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Chapter 1 
INTRODUCTION 
1.1 Cardiac excitation-contraction coupling  
Cardiac excitation-contraction (EC) coupling is a tightly regulated process, which is 
required for the heart to maintain proper functions [1].  These functions include pumping blood 
to the body, supplying oxygen and nutrients, eliminating waste and thermoregulation.  These 
complex organ level processes can be broken down to the level of the individual cardiomyocyte 
(CM), the major structural and functional unit of the heart, responsible for contraction.  This can 
be further broken down to the mechanisms that regulate CM physiology specifically EC coupling 
(Figure 1).  EC coupling is the delicate balance between electrical excitation and mechanical 
contraction.  This process is largely driven by the second messenger calcium (Ca) which links 
excitation and contraction and enables the heart to maintain adequate cardiac output to meet 
the needs of the body.  However, in acquired and genetic situations in which the heart is not 
capable of supporting the needs of the body, heart failure ensues. 
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Figure 1.  Schematic of human cardiac excitation-contraction coupling.  A, Schematic of key EC 
coupling protein localization and function.  Note the key sarcolemma Ca handling proteins: L-
type Ca channel, NCX and PMCA as well as the intracellular SR calcium transporter SERCA.  
B, Cardiac action potential recording.  C, Ca handling transient.  D, Contraction trace.  B – D 
demonstrates the temporal relationship between electrical depolarization, Ca flux and 
contraction. (Adapted from, Knollmann B., Ph.D. Dissertation. 1999). 
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Cardiomyocyte electrophysiology  
Under physiological conditions each ventricular cardiac cycle is regulated by an array of 
ion channels and transporters that actively and passively regulate CM membrane potential 
(Figure 2) [2].  Changes in the membrane potential may result in CM depolarization, which 
during normal EC coupling is initiated by the fast inward sodium current (INa) (Figure 1 B and 
Figure 2 A and B).  This rapid depolarizing current is responsible for Phase 0 of the human 
cardiac action potential morphology (Figure 2 B).  Inactivation of the inward sodium current 
results in Phase 1 of the action potential producing a relatively small downward defection also 
referred to as the “notch”; that is driven by the outward potassium current including (Ito).  Next, 
during Phase 2 of the action potential L-type Ca channels (ICa) open enabling the influx of Ca 
concurrent with potassium efflux through slow delayed potassium channels.  This is indicated by 
the plateau of the action potential morphology (Figure 2 B).  Once the L-type Ca channels close, 
the outward potassium channels (IKr and IKs) dominate the membrane potential resulting in 
repolarization represented as Phase 3.  Finally, the CM membrane is returned to the resting 
state, Phase 4, which is largely driven by the CM conductance for potassium and inward rectifier 
potassium ion channels (IK1) (Figure 2 B). 
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Figure 2.  Human cardiac electrophysiological characteristics.  A, Schematic of ion movement 
across CM membrane indicating calcium and sodium movement down their electrochemical 
gradient into the CM and potassium movement out of the CM.  B, Action potential trace, 
depicting responsible currents for each phase of the action potential morphology.  Phase 0 is 
initiated by depolarizing fast activating sodium current I
na
.  Next, the phase 1 transient activating 
potassium current I
to
 drives the relatively small downward notch.  The balance between L-type 
calcium current I
ca
 and potassium currents I
Kr
 and I
ks
 is responsible for the phase 2 plateau.  
Finally, the potassium current I
K1 
dominates the membrane potential repolarizing the CM and 
returning it to Phase 4.  (Adapted from, George A., The Journal of Clinical Investigation. 2013; 
123(1):75-83). 
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Cardiomyocyte calcium handing  
 The change in CM electrical potential drives changes in CM Ca handling (Figure 1 C).  
At steady state the relatively small amount of free Ca in the cytoplasm is not sufficient to 
achieve threshold and initiate CM contraction [3].  After initial depolarization of the CM L-type 
Ca channels open producing a relatively small increase in intracellular Ca (Figure 1 C); this Ca 
is responsible for activating receptors in the sarcoplasmic reticulum (SR), the intracellular Ca 
store, in a mechanism known as calcium induced calcium release (CICR).  This enables the SR 
to release a relatively large amount of free Ca into the cytoplasm resulting in the upward spike 
of the Ca transient morphology (Figure 1 C).  This Ca is then free to bind to intracellular Ca 
binding sites (e.g., troponin C) to effect contraction.  There are two primary Ca removal 
pathways responsible for Ca efflux (Figure 1) from the cytoplasm, the sarcoendoplasmic 
reticulum Ca ATPase (SERCA) and the Na/Ca exchanger (NCX) with other non-NCX and non-
SR removal pathways such as the plasma membrane Ca ATPase (PMCA) and mitochondria 
contributing less than 5%.  These removal pathways are responsible for returning the CM to the 
resting Ca concentration [4] resulting in Ca decay as indicated by the decline of the Ca transient 
morphology (Figure 1 C). 
Cardiomyocyte contractility 
 The interaction between Ca and the myofilament regulates sarcomere and cell 
shortening, resulting in contraction of the CM.  Ca released from the SR binds to intracellular Ca 
sites including the troponin complex of the thin filament (Figure 1).  The troponin complex is 
composed of three subunits: troponin C, which directly binds Ca acting as a Ca dependent 
regulator of contraction [3].  Troponin I the inhibitory subunit, which inhibits the actin and myosin 
interaction, acting as a negative regulator of contraction, and the troponin T subunit which binds 
tropomyosin stabilizing the troponin-tropomyosin complex.  The majority of free Ca binds to 
troponin C resulting in a conformation change in the troponin I subunit.  This conformation 
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change moves troponin I out of an inhibitory positon and enables myosin within the thick 
filament to interact with actin, of the thin filament, enabling cross bridge formation resulting in 
cell shortening and contraction (Figure 1 D). 
 
1.2 Induced pluripotent stem cell technology 
 
Human induced pluripotent stem cells 
In 2007 two seminal papers were published in the journals Cell and Science that 
represented a significant scientific advance in stem cell technology.  Yamanaka and colleagues 
[5] and Thomson and colleagues [6] demonstrated that stem cells with similar characteristics as 
human embryonic stem cells (hESC) could be generated from human fibroblasts by expressing 
specific pluripotency genes (e.g., Oct4, Sox2, Klf4, and C-Myc/L-Myc).  These cells were termed 
human induced pluripotent stem cells (hiPSCs) (Figure 3).  HiPSCs, like hESCs, are capable of 
self-renewal and pluripotency.  For decades, since the establishment of hESCs in 1998 [7], by 
James Thomson, researchers have been working to unlock the full potential of hESCs.  
However, efforts have been hampered by ethical, political and legal controversy surrounding 
hESC use.  
The establishment of hiPSCs represents a cell source with similar promise as hESCs, 
however, with the added benefits of avoiding the negative issues surrounding their use.  In 
addition hiPSCs have the unique attribute of being derived from healthy or patient’s somatic 
cells, representing disease-specific stem cells, a major advance for regenerative medicine and 
disease modeling.  Initial hiPSC reprogramming strategies, while sufficient, were limited by low 
efficiency (< 1 %), dependence on mouse embryonic fibroblasts as feeder layer and retrovirus 
or lentivirus reprogramming strategies (Figure 3 A) that may result in transgene integration in 
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the host genome and potential adverse effects, such as tumor formation.  Since then additional 
reprogramming strategies have been developed to address these pitfalls.  For instance feeder-
free and integration-free based methods such as sendai virus and plasmid (i.e., 7 F2 and Epi 5) 
(Figure 3 A and Figure 4 B and D).  These methods typically express similar pluripotency genes 
and have enabled many groups in basic science and industry to generate hiPSC from various 
somatic cell sources.  Most notably fibroblasts (Figure 5 A) from skin punch biopsy and 
peripheral blood mononuclear cells from routine blood draw.  Plasmid-based reprogramming 
factors are introduced into somatic cells by transfection systems that have become standard at 
many institutions (Figure 4 A and C).  For standardization, each of the hiPSC lines is validated 
by demonstration of key hESC-like features such as morphology (Figure 5 B) and expression of 
pluripotency markers (Figure 5 C and D).  The implementation of hiPSC technology has enabled 
the development of novel directed differentiation protocols to transform hiPSC to various cell 
types; such as neurons, hepatocytes, endothelial cells and cardiomyocytes.  
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Figure 3.  hiPSC reprogramming.  A, Reprogramming strategies including integrating and non-
integrating viral based methods and non-integrating plasmid, RNA and protein based methods.  
B, Isolated somatic cells (e.g., fibroblast or peripheral blood mononuclear cells) expanded in 
culture and reprogrammed by exposing the somatic cells to reprogramming factors (see figure 
4) to generate induced pluripotent stem cells, C.  (Adapted from, Friedrichs et al, TCM 2012). 
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Figure 4.  Reprogramming systems and plasmids.  A, Amaxa biosystems nucleofector II 
("Nucleofector™ 2b Manual." Lonza. Web. 2015).  B, Combination 7F-2 plasmids expressing 
factors OCT4, SOX2, c-MYC, NANOG, KFL4 and LIN28 (Junying Y. et al., PLoS ONE.  2011; 
doi:10.1371/journal.pone.0017557).  C, ThermoFisher Scientific neon transfection system 
("Neon® Transfection System. Product Information. Web. 2015).  D, Epi5 episomal iPSC 
reprogramming vectors expressing reprogramming factors OCT4, SOX2, KFL4 L-MYC, LIN28. 
Epi5 plasmids are 2
nd
 generation plasmids that benefit from the addition of a p53 suppressor 
gene, which improves reprogramming efficiencies.  And contain L-MYC instead of the highly 
tumorigenic c-MYC (Episomal IPSC Reprogramming Kit." Life Technologies. Web. 2013.)  
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Figure 5.  hiPSC validation.  Bright field images of A, Somatic cells (cardiac fibroblast) 
expanded in culture.  And B, typical morphology of reprogrammed hiPSC colony.  C, 
Immunofluorescence images of hiPSC for DAPI (blue) and pluripotency markers OCT4 (green) 
and NANOG (red) demonstrating successful reprogramming and generation of hiPSC.  Scale 
bar 100 µm.  D, PCR analysis for pluripotency marker OCT4 in two independently generated 
hiPSC lines, fibroblast included as negative control.  (Representative hiPSCs images A – C and 
example PCR analysis D shown are from Vanderbilt hiPSCs). 
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Human induced pluripotent stem cell derived cardiomyocytes 
Substantial progress has been made in hiPSC-CM cardiac differentiation protocols, 
evolving from the inefficient and variable aggregation-based method (i.e., embryoid body (EB)).  
Traditional EB based methods generate spontaneously beating CMs by forced aggregation of 
hiPSCs, thought to mimic the environment of the early embryo, under high serum conditions.  
This method resulted in low yields of hiPSC-CMs (< 1 %).  However, since then more robust 
monolayer-based methods (i.e., > 80 % hiPSC-CMs) such as the Matrigel sandwich method 
(Figure 6 A) have been developed, which benefit from the defined sequential application of 
growth factors and cytokines targeting distinct signaling pathways implicated in human 
cardiomyogenisis (e.g., transforming growth factor – β (TGFβ), activin A and BMP4).  This 
method provides a significant advance in cardiac differentiation methodology by greatly 
increasing hiPSC-CM yield for most laboratories.  However, the Matrigel sandwich method was 
limited by the undefined chemical nature of the reagents and high cost of Matrigel.  For these 
reasons a small molecule method (Figure 6 B) [8-10] was developed, based on the temporal 
modulation of the Wnt signaling pathway, and a completely chemically defined monolayer-
based method [10].  To characterize and validate cardiac differentiation efficiency hiPSC-CMs 
are evaluated for cardiac phenotype (Figure 7 A) such as spontaneous beating and expression 
of cardiac specific markers (Figure 7 B and C). 
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Figure 6.  Monolayer cardiac differentiation methods.  A, Matrigel sandwich method. Work flow 
demonstrating the stage specific sequential application of growth factors and proteins, including 
the addition of a thin layer of ECM (i.e., matrigel).  (Adapted from Zhang J et al., Circulation 
Research.  2012; 111(9):1125-36)B, Small molecule based method.  Work flow displaying the 
temporal modulation of the Wnt signaling pathway.  Early (day 0) activation with the small 
molecule Wnt agonist, CHIR99021, and late (day 3) inhibition with Wnt antagonist, IWR-1.  
(Burridge P. et al., Nature Methods.  2014; 11(8): 855–860). 
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Figure 7.  hiPSC-CM validation.  A, Bright field image of a 2D monolayer sheet of hiPSC-CMs.  
Courtesy of Mr. Calvin Sheng  B, Immunofluorescence staining of hiPSC-CMs for cardiac 
markers (green) troponin T (left panel) and α-actinin (right panel), and nucleus DAPI (red).  
Scale bar 20 µm. C, FAC analysis demonstrating greater than 90 % pure population of hiPSC-
CMs, cardiac markers troponin T (TnT), ryanodine receptor (RYR) and α-actinin. 
(Representative hiPSC-CM images A – B and example FAC analysis C shown are from 
Vanderbilt University hiPSC-CMs derived from hiPSC line CC2).  Panel B and C courtesy of Dr. 
Young Wook Chun. 
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State of hiPSC-CM E-C coupling 
HiPSC-CMs recapitulate key aspects of human CM biology.  For example hiPSC-CMs 
contain the appropriate machinery to contract in vitro and respond appropriately to electrical 
stimulation.  HiPSC-CMs express key sarcomeric and Ca handling proteins, similar to native 
myocardium [9, 11] and recapitulate several inherited heart disease phenotypes [12, 13]; thus 
representing a theoretically unlimited source of human CMs for experimental studies.  The utility 
of these cells has reproducibly been demonstrated for basic research, drug discovery, and 
preclinical cardiotoxicty.  However, there remains a major hurdle which is the clinical 
translatability of these cells and results obtain from them.  The majority of reports suggest that 
hiPSC-CMs, while useful, represent a relatively immature phenotype.  For example (Table 1) 
[11] compares immature CMs to adult CMs and highlights key structural, molecular and 
functional differences in hiPSC-CMs and their adult counterparts.  Structurally, like immature 
CMs, hiPSC-CMs are circular and small relative to adult ventricular CMs and display 
unorganized sarcomeres with decreased sarcomere length.  In addition hiPSC-CMs lack T-
tubules, which are deep invaginations in the CM membrane, necessary for uniform EC coupling 
properties.  Molecularly several isoforms present in adult-CMs are poorly expressed in immature 
CMs and hiPSC-CMs.  For example, hiPSC-CMs primarily express the fetal slow skeletal 
troponin I (ssTnI) instead of the mature adult cardiac troponin I (cTnI), even with extended time 
in culture (e.g., 9 months) [14]. 
Functionally the EC coupling of hiPSC-CMs have not been investigated in great detail. 
However, it is accepted that hiPSC-CM electrophysiological properties include significantly 
reduced upstroke velocity and depolarized resting membrane potentials characteristic of 
immature CMs.  With respect to Ca handling properties hiPSC-CMs generated by EB-based 
cardiac differentiation methods, at various ages (e.g., day 7 – 60), display either lack of caffeine 
releasable SR Ca stores [11] or their presence only in a sub-population of CMs [12, 15-17], 
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suggesting immature or underdeveloped Ca handling properties.  A recent report characterized 
Ca handling of hiPSC-CMs generated by the monolayer-based Matrigel Sandwich method [9].  
However, this study only evaluated twitch Ca handling properties in response to different pacing 
rates, while SR content and function were not evaluated.  Moreover, Ca fluorescence 
measurements were obtained from clumps or clusters of cells, not single cells.  These cases 
highlight the need for a detailed systematic evaluation of these properties in single hiPSC-CMs.  
The contractile properties of hiPSC-CMs remain among the least studied parameters of 
EC coupling.  Various methods have been attempted to assess contractility of hiPSC-CMs 
however single cell measurements have been notoriously difficult to obtain.  Hence, many 
researchers have transitioned to multicellular preparations (e.g., EHTs, BioWire or 
XCELLigence).  These methods provide high-content readout of contractile function and when 
coupled with a Ca sensitive dye, enable simultaneous Ca and contractile measurements [18].  
However, as these are multicellular preparations they are inherently heterogeneous, which may 
mask the individual CM properties and are extremely costly.  To elucidate what makes the 
hiPSC-CM contractile phenotype, single cell analyses are required. 
Traditionally, the method of choice for measuring single rod shaped adult-CM contractile 
properties has been video-based microscopy, evaluating changes in cell or sarcomere length 
[19].  However, this method has not been routine for hiPSC-CMs, which exhibit relatively 
immature sarcomere architecture including circular shape and unaligned myofilament alignment.  
In addition, under standard culture condition, hiPSC-CMs, do not display a dominant contraction 
axis, as their edges are firmly attached to the culture substrate and do not move with each 
contraction cycle.  Instead the inside of the cell (i.e., nuclear region) displays observable 
movement [20, 21]. 
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For these reasons single cell contractility methods (e.g., traction force microscopy 
(TFM), atomic force microscopy (AFM) or image-based rhythmic methods) have been used [19] 
however these methods have certain caveats.  For example; AFM is highly invasive and not 
fitting for long term measurements.  In addition several methods have been developed focusing 
on image or pixel based analysis of non-shortening hiPSC-CMs (i.e., no change in cellular 
geometry).  These measurements are not ideal as they represent intracellular movement 
instead of whole cell movement which may hinder detailed studies of hiPSC-CM mechanical 
properties [7, 9].  Moreover, impedance changes and changes in beat frequency are not 
representative of hiPSC-CM mechanical properties. 
Previous attempts to evaluate single hiPSC-CM contraction, using video edge-detection, 
to evaluate changes in cellular shortening, of “early-stage” hiPSC-CM, (i.e., day 20 – 40) 
suggest that these hiPSC-CMs, display contractions of approximately 5 % of their resting cell 
length.  In addition the same report suggests late-stage hiPSC-CMs (i.e., day 100 – 120) 
contract approximately 10 % and exhibit slowed contractile kinetics, relative to the early stage 
hiPSC-CMs [22].  The authors conclude that late stage hiPSC-CMs display “matured” contractile 
properties however these results have yet to be reproduced.  The lack of reliable user-friendly 
contractility methods limits the study of hiPSC-CM contractility in most laboratories thus limiting 
our understanding of hiPSC-CM EC coupling. 
To the best of our knowledge no report has compared hiPSC-CM E-C coupling 
properties (i.e., electrophysiology, Ca handling and contractility) to adult human CMs under 
identical experimental conditions.  Currently there is little available information regarding the 
human CM in vitro phenotype this due to the quality of human samples and harsh isolation 
protocols that may alter CM physiology.  For this reason a side-by-side comparison of hiPSC-
CMs and human adult-CMs would be of great use to the field.  However, because of the lack of 
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available human adult cardiac tissue for such comparison animal adult CMs (e.g., rabbit-CMs) 
are the next logical step. 
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Table 1.  Comparison between immature and adult CMs.  (Adapted from Yang X. et al., 
Circulation Research 2014; 114(3):511-23). 
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1.3 Heart failure 
Heart failure (HF) is a leading cause of morbidity and mortality in the developed world, 
affecting 5.7 million Americans (Figure 8) and accounting for over 280,000 US deaths annually 
[1].  This creates an enormous financial burden that is projected to result in 77 billion dollars of 
direct cost, in the US alone by the year 2030 (Figure 8 B).  Primary cardiomyopathy, defined as 
abnormal heart muscle structure and function in the absence of significant coronary artery 
disease is increasingly recognized as an important cause of severe HF, particularly in the 
young.  Moreover, because most primary cardiomyopathy cases have a genetic root cause in 
sarcomere components, it is widely accepted that a better understanding of their molecular 
pathophysiology will elucidate the pathogenesis of HF in general, and guide development of 
future therapies and treatments.  For example studies in transgenic mice carrying various 
mutations indicate autosomal dominant sarcomere mutations are a causal factor.  However, 
these mutations have yet to be investigated in intact human CMs. 
Primary sarcomeric cardiomyopathy (Figure 9) can be subdivided into three categories 
hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) and restrictive 
cardiomyopathy (RCM).  HCM is clinically characterized by preserved systolic function with 
impaired diastolic function and affects 1 in 500 people.  Classically HCM is accompanied by 
thickening of the heart muscle, typically the septum (Figure 9 C).  However, this is not a 
dependent factor for sudden cardiac death (SCD) as there have been rare reports of arrhythmia 
without CM hypertrophy.  At the level of the CM, HCM displays inherent defects such as 
myofilament disarray associated with causal mutations, in both thick and thin sarcomere 
components, such as β-myosin heavy chain encoded by,MYH7, and cardiac troponin T encoded 
by TNNT2.  DCM is characterized by impaired systolic function and linked to sarcomere 
mutations in the thick and thin filament, for example, proteins such as titin encoded by TTN, α-
cardiac actin encoded by ACTC1 and tropomyosin encoded by TPM1.  Structurally DCM hearts 
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are enlarged with thin walls including the septum (Figure 9 B).  RCM is characterized by 
restrictive diastolic filling of non-hypertrophied, non-dilated ventricles (Figure 9 D); normal or 
reduced diastolic volumes; and normal or near normal systolic function.  RCM in particular 
carries a poor prognosis, with 50% mortality within 2 years of diagnosis.  RCM is linked to 
sarcomeric proteins including cardiac troponin T encoded by TNNT2 and cardiac troponin I 
encoded by TNNI3. 
Attempts to separate cardiomyopathies into distinct categories have failed.  It is 
becoming increasingly clear that there is considerable overlap and in some cases one form may 
progress to another.  For example HCM can transition to DCM in end stage HF.  Nevertheless 
each form of sarcomeric cardiomyopathy can dramatically increase the risk of progressive HF, 
arrhythmia and SCD. 
In principle, hiPSCs are an attractive platform to meet the need for cultured human CMs.  
HiPSC-CMs have many potential application including drug screening and toxicology, disease 
modeling and regenerative medicine.  For instance hiPSC-CMs derived from hiPSCs of patients 
with inherited cardiomyopathies have permitted examination of the effects of specific genetic 
mutations at the cellular level [12, 13].  Current HF treatments, including surgery transplant or 
implantable cardioverter defibrillator (ICD), are not ideal as they require rare donor hearts or 
invasive procedures.  Current pharmacological treatments are largely palliative and focus on 
reducing blood pressure (e.g., ACE inhibitors) and water retention (e.g., Diuretic) (Figure 10) to 
reduce the work load of the heart.  As an additional treatment agents that directly target the CM 
and modulate key components of EC coupling are approved.  For example, positive inotropic 
agents such as β-adrenergic agonists, phosphodiesterase inhibitors and cardiac glycosides 
(Figure 10 and Figure 11) have all been used to treat HF but primarily for symptomatic relief.  
Hence, drug discovery efforts would benefit from an in vitro human CM model with better 
translatability.  
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Figure 8.  Heart failure projections. A , Graph depicting a 25 % projected increase of heart 
failure cases in the US, by the year 2030.  B, Graph demonstrating 215 % projected increase in 
direct cost.  (Projected increased indicated by the red arrows).  (Modified from Heidenreich PA. 
et al., Circulation.  2011; 123:933-944). 
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Figure 9.  Sarcomeric cardiomyopathy structural characteristics.  A, Normal heart.  B, Dilated 
cardiomyopathy (DCM) heart displaying hallmark dilated left ventricle including septum and free 
wall and enlarged chamber size.  C, Hypertrophic cardiomyopathy (HCM) heart displaying 
characteristic thickening of the left ventricle septum and free wall including reduced chamber 
size.  D, Restrictive cardiomyopathy (RCM) heart displaying moderate to mild hypertrophy and 
normal chamber size.  (Modified from, Blausen Medical Communications, Journal of Medicine. 
2014 doi:10.15347/wjm/2014.010. ISSN 20018762). 
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Figure 10.  Heart failure therapies.  Flow chart depicting key nodes and interventions for heart 
failure. HF is clinical defined as decreased cardiac output (indicated in red).  Decreased cardiac 
output activates feedback pathways that increase cardiac preload and blood pressure.  Chronic 
stimulation of these processes ultimately increases the work demand of the heart and worsens 
the condition.  Inhibition of the renin-angiotensin system, to decrease blood pressure and 
diuretic to reduce sodium and water retention are traditional first line therapies.  Therapies that 
directly affect the cardiomyocyte include inotropic agents and digoxin (indicated in green) these 
agents provide little benefit for mortality.  AT
1
 (angiotensin receptor) and β (β adrenergic 
receptor).  (Adapted From, Bruton LL, Chabner BA, Knollmann BC; Goodman & Gilman’s The 
Pharmacological Basis of Therapeutics, 12
th
 Edition: www.accessmedicine.com). 
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Figure 11.  β- Adrenergic signaling pathway.  Upon ligand binding to the G protein–coupled 
receptor a conformation change occurs which enables the Gα subunit to dissociate from  the Gβ 
and Gγ.  The dissociated Gα then activates the enzyme adenylate cyclase (AC) which then 
activates the second messenger cyclic adenosine monophosphate (cAMP).  Activation of cAMP 
leads to activation of protein kinase A (PKA) which then phosphorylates targets that ultimately 
enhance contractile properties.  Phosphorylation of phospholamban (PLB) results in increased 
SR Ca content.  Phosphorylation of the L-type calcium channels result in increased intracellular 
Ca and enhanced CICR, during each contraction cycle.  Phosphorylation of ryanodine (RYR) 
increases the amount of Ca that extrudes from the SR during each beat.  And phosphorylation 
of TnI increases the rate of CM relaxation. 
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1.4 Objective 
Here, I set out to characterize the EC coupling properties of single hiPSC-CMs including 
contractile performance with the goal of better understanding the utility of these cells for basic 
research and drug discovery purposes.  I elucidate the steady-state EC coupling properties of 
control “healthy” hiPSC-CMs.  In these experiments, I focused on detailed characterization of 
EC coupling parameters; electrophysiology, Ca handling [23] and contractility (i.e., cell 
shortening).  To achieve this, I developed and implemented a novel culture method that enables 
assessment of single hiPSC-CM contractile properties in vitro [24].  For standardization, and 
assessment of hiPSC-CM maturation status I elucidate these properties under identical 
experimental conditions with hiPSC-CMs generated at different institutions and adult ventricular 
animal-CMs (i.e., rabbit and mouse).  To the best of our knowledge this work represents the first 
systematic detailed characterization of hiPSC-CM EC coupling properties. 
Next, I demonstrate the utility of hiPSC-CMs for disease modeling and drug discovery 
and provide support for a potential HCM MYH7 mechanism.  These findings, along with the 
detailed studies defining normal hiPSC-CM properties will aid future functional characterization 
of disease specific hiPSC-CMs as well as the effect of novel and known pharmacological 
agents. 
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Chapter 2 
EXCITATION - CONTRACTION COUPLING OF HIPSC-CM 
2.1 Chapter Abstract 
The lack of reliable in vitro methods to evaluate human cardiomyocyte biology, 
contributes to high mortality and drug attrition rates for heart diseases.  In addition, 
inconsistencies in cellular reprogramming and cardiac differentiation, as well as lack of available 
methods to assess hiPSC-CM EC coupling parameters have resulted in conflicting reports, thus 
limiting our understanding of hiPSC-CMs and the utility of these cells for modeling heart 
diseases.  Here, I set out to characterize EC coupling properties of single “healthy” hiPSC-CMs.  
Focusing on three EC coupling parameters [electrophysiology, Ca handling and contractility 
(i.e., cell shortening)] in an effort to compare hiPSC-CMs generated independently from different 
hiPSC lines, at different institutions and correlate these results with that obtained from acutely 
isolated primary adult-CMs (i.e., rabbit-CM and mouse-CM), under identical experimental 
conditions.  We found that hiPSC-CMs have relatively comparable electrophysiological 
properties as do adult CMs.  Likewise the Ca handling comparison revealed mature Ca handling 
properties.  With the implementation of a novel culture method termed the, “Matrigel mattress,” I 
quantify the contractile properties of single hiPSC-CMs, as well as demonstrate reproducibility 
across groups.  I further demonstrate hiPSC-CMs have comparable contractile properties as 
adult-CMs including contractile kinetics comparable to that of adult rabbit-CMs.  Taken together, 
these data demonstrate hiPSC-CMs display relatively mature EC coupling properties including 
electrophysiology, Ca handling and contractility.  And implementation of a novel culture method 
enables rapid generation of robustly contracting hiPSC-CMs and enhances maturation.  
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2.2 Introduction 
Excitation-contraction (EC) coupling is essential for heart function [1].  However, detailed 
mechanistic studies of human cardiomyocyte (CM) EC coupling in both basic science and drug 
discovery have been limited by lack of an appropriate human CM model.  The use of acutely-
isolated primary human CMs is hampered by rare availability and technical limitations.  Coupled 
with increasing prevalence of heart failure, lack of current therapies, rising drug attrition rates 
and cardiac toxic adverse effects, there is a great need for in vitro human CM evaluation. 
The recent establishment of human induced pluripotent stem cells (hiPSCs) has 
provided a new approach for obtaining human CMs [5, 25].  hiPSCs, generated from mature 
somatic cells harvested from patients, are analogous to human embryonic stem cells (hESCs); 
while avoiding the ethical controversies surrounding their use [26].  Hence, hiPSCs represent a 
renewable cell source of patient- or disease-specific tissue, potentially avoiding immune 
rejection [27].  Additionally, hiPSCs can be differentiated to cells of all three germ layers, 
including cardiac muscle [25] thus enabling generation of CMs from different genetic 
backgrounds.  
In mature ventricular CMs, EC is initiated by membrane depolarization followed by influx 
of Calcium (Ca) via L-type Ca channels.  Entering Ca triggers Ca-induced Ca release (CICR) 
from the sarcoplasmic reticulum (SR) via ryanodine receptor Ca release channels [3]. The 
ensuing rise in intracellular Ca binds to the troponin complex and activates myofilament resulting 
in cellular contraction and shortening [28].  For relaxation to occur, Ca is removed from the 
cytoplasm, by two primary removal pathways: the sarcoendoplasmic reticulum Ca  ATPase 
(SERCA) and the Na/Ca exchanger (NCX), with other, non-NCX non-SR removal pathways 
such as plasma lemma Ca ATPase and mitochondria contributing less than 5%, returning the 
CM to the resting cell length [4].  Given Ca’s central role in linking electrical activation, through 
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cellular depolarization, and contraction, dysfunctional CM Ca handling has been associated with 
contractile dysfunction, arrhythmia and other heart diseases [29, 30]. 
Earlier studies of the functional properties of hiPSC-CMs have largely focused on 
electrophysiological properties, hiPSC-CMs express all ion channels naturally found in adult 
human left ventricular tissue, albeit at various levels [31, 32].  Additionally, hiPSC-CMs, 
generated using the monolayer Matrigel sandwich method display human-like action potential 
morphology and robust L-type Ca currents [9].  However, the Ca handling properties and 
contractile properties remain not well understood; moreover EC coupling parameters have not 
been compared to adult-CMs under identical experimental conditions.  To date, immature Ca 
handling and SR function have been associated with hiPSC-CMs [12, 13, 15, 31].  And while 
contractile properties have been studied, in hiPSC-CMs generated by monolayer based 
methods, these studies are limited as they evaluate beat frequency as a surrogate of cellular 
contractility. 
A major concern for use of hiPSC-CMs is their relatively “immature” phenotype which 
may result in substantial differences in their physiology when compared to native CMs.  With 
respect to EC coupling, earlier reports have indicated that hESC-CMs and hiPSC-CMs depend 
primarily on trans-sarcolemmal Ca entry for contraction [3, 11, 28].  Moreover, the usefulness of 
hiPSC-CMs depends, in part, on their contractile properties which in turn relies on the Ca 
handling of these cells [28].  This highlights the need for direct comparison of EC coupling 
properties of hiPSC-CMs and adult-CMs under identical experimental conditions. 
Here, I characterize EC coupling of single hiPSC-CMs. I specifically focus on 
comparison of electrophysiological, Ca handling and contractile properties of hiPSC-CMs 
generated from multiple hiPSC lines, independently by different laboratories, to that of acutely-
isolated adult rabbit and mouse ventricular-CMs.  To the best of our knowledge, this is the first 
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report of a comprehensive, systematic evaluation of EC coupling in single normal hiPSC-CMs 
derived by monolayer-based cardiac differentiation methods.  We find that hiPSC-CMs display 
relatively mature electrophysiological properties including comparable amplitude and resting 
membrane potential.  We further show hiPSC-CMs from different laboratories exhibit 
comparable and reproducible intracellular Ca handling including robust and functional SR Ca 
stores.  Finally, I present the development and implementation of a novel culture method to 
evaluate hiPSC-CM contractility.  I elucidate the contractile properties of single hiPSC-CMs and 
demonstrate reproducibility across laboratories and comparable properties to that of acutely-
isolated adult rabbit-CMs.  Taken together, our results suggest hiPSC-CMs generated by 
monolayer-based methods exhibit relatively mature EC coupling properties in vitro. 
2.3 Materials and methods 
The University Committee on Use and Care of Animals at Vanderbilt University Medical 
Center approves all animal protocols. All animal protocols conformed to the Guiding Principles 
in the Care and Use of Animals of the American Physiological Society.  Data averaged from 
multiple days were used for analysis.  All chemicals, unless otherwise specified, were obtained 
from Sigma (St. Louis, MO).  All Protocols were approved by Vanderbilt University Medical 
Center Institutional Review Board. 
Human iPSC derivation and culture 
Human induced pluripotent stem cells (hiPSCs) from healthy volunteers were 
independently generated, as previously described, by three laboratories Stanford University 
[33], Vanderbilt University [34], and University of Wisconsin [9, 35].  All protocols were approved 
by the respective institutions Institutional Review Board. Three different methods of 
reprogramming were used.  Briefly, Stanford hiPSC lines, 13FLVN0C1 and SCVI13 were 
derived from adult fibroblast using lentivirus based reprogramming [20].  Vanderbilt hiPSC line, 
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CC2 was derived from dermal fibroblast by non-integrating episomal based reprogramming,  
and CJ1-001 was derived from peripheral blood mononuclear cells by non-integrating episomal 
based reprogramming [36].  Wisconsin hiPSC line, DF19-9-11T, was derived from neonatal 
foreskin fibroblast by vector and transgene free episomal based reprogramming [22].  For all 
reprogramming individual colonies with typical hESC morphology were picked at day 17 to 30 
and clonally expanded.  All hiPSCs exhibit normally karyotype. hiPSC lines were routinely 
maintained on Matrigel, growth factor-reduced 1:200 (Corning) or on Synthemax II-SC coated 
plates in mTeSR1 medium (Stemcell Technologies) or E8 medium (Stanford University). Cells 
were passaged every 4 days using 0.5 mM EDTA (Life Technologies) in D-PBS without CaCl2 or 
MgCl2 (Life Technologies).  2 µM thiazovivin (Selleck Chemicals) or 10 µM Rho kinase inhibitor 
Y-27632 (CalBiochem) was added for the first 24hrs after passaging.  Cells were maintained at 
37ºC, with 5% CO2 and 5% O2.  
Monolayer-based cardiac differentiation 
Two protocols were used for induction of cardiac differentiation at the three institutions.  
Both protocols yield 80-95% troponin T positive cells that spontaneously contract from day 7:  
1. Matrigel Sandwich Induction (University of Wisconsin [9] & Vanderbilt University [34]).  
Briefly, hiPSCs (>p20) were incubated with Versene solution (Invitrogen) (1 mL/well 6-
well plate) at 37ºC for 5 minutes to dissociate cells.  Cell were seeded on Matrigel 
growth factor-reduced (Corning) coated plates at a density of 100,000 cells/cm2 in 
mTeSR1 medium (Stemcell Technologies) supplemented with 10 µM Rho kinase 
inhibitor Y-27632 (CalBiochem).  The mTeSR1 medium was changed daily for 4 days at 
which point the monolayer reached ~80% confluence.  A thin layer of Matrigel 0.5 mg 
was overlaid in ice-cold mTeSR1 medium.  When cells reached 100% confluence, 
medium was changed to basal medium RPMI 1640 (11875, Life Technologies) 
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supplemented with B-27 without insulin (Invitrogen) containing Activin A (100 ng/mL, 
R&D Systems) and Matrigel (0.5 mg Matrigel/6-well plate); this is referred to as day 0.  
On day 1, medium was changed to RPMI 1640 medium plus B-27 without insulin 
supplement (Invitrogen) without Matrigel and supplemented with BMP4 (5-10 ng/mL, 
R&D Systems) and (bFGF 5-10 ng/mL, Invitrogen) for 4 days.  At day 5, RPMI 1640 
medium plus B27 complete supplement (Invitrogen) was added and medium changed 
every 3 days until dissociation.  
2. Small Molecule Induction (Stanford University [10, 37]).  Briefly, hiPSCs (>p20) cultured 
in E8 medium were split at 1:12 ratio.  Cells were grown for 4 days at which time they 
reached ~80% confluence.  This is referred to as day 0; medium was changed to cardiac 
differentiation medium consisting of RPMI 1640 (11875, Life Technologies) and B-27 
minus insulin supplement (A1895601, Life Technologies) supplemented with 10 µM or 6 
µM CHIR99021 (LC Laboratories) for day 0 to day 1.  On day 1 medium was changed to 
cardiac differentiation medium.  On day 3 medium was changed to cardiac differentiation 
medium supplemented with 5 µM IWR-1 (Sigma).  On day 5 medium was changed to 
cardiac differentiation medium.  Medium was changed on day 7 to cardiac medium 
consisting of RPMI1640 (11875, Life Technologies) and B-27 supplement (17504, Life 
Technologies).  At day 10 medium was changed to metabolic selection medium 
consisting of RPMI 1640 without glucose (11879, Life Technologies) plus B27 without 
insulin.  On day 12 medium was changed to RPMI 1640 medium (11875, Life 
Technologies), 2 % B-27 supplement (Invitrogen), and 1 % Pen-Strep (Life 
Technologies) until dissociation.  
hiPSC-CM dissociation, storage and plating 
HiPSC-CMs were dissociated and plated as described [23].  Briefly hiPSC-CMs were 
washed with D-PBS without CaCl2 or MgCl2 (Life Technologies) and incubated with TrypLE 
Express (Life Technologies) for 10 to 15 minutes at 37ºC to dissociate cells.  For 
32 
cryopreservation hiPSC-CMs were suspended in 90% FBS, 10% DMSO and stored in liquid 
nitrogen at day 30 after cardiac differentiation.  Prior to plating hiPSC-CMs were filtered (100 
µm) (Falcon) and plated at low density (40,000 cells) on either control substrate (Matrigel growth 
factor-reduced 1:60 in DMEM F12) or Matrigel mattress coated dish, as described below) in 
approximately 200 µl solution containing: RPMI 1640 medium (11875, Life Technologies), 2 % 
B-27 supplement (Invitrogen), and 1 % Pen-Strep (Life Technologies).  hiPSC-CMs were 
maintained at 5 % CO2 and 21 % O2.  Medium was changed every day and experiments were 
performed 3 - 7 days after plating.  
For contractility experiments cryopreserved hiPSC-CMs, SCVI13 (Stanford), were 
thawed and plated on Matrigel (1:200 dilution) for 4 days to allow CM contractile machinery to 
recover from cryopreservation prior to plating on Matrigel mattress.  
Primary myocyte isolation  
Ventricular myocytes from mouse and rabbit were isolated by a modified 
collagenase/protease method as previously described [38].  All the experiments conducted in 
Tyrode’s solution containing (in mM): CaCl2, NaCl 134, KCl 5.4, MgCl2 1, glucose 10, and 
HEPES 10, pH adjusted to 7.4 with NaOH.  Final concentration of Ca was 2 mM. 
Measurement of intracellular Ca 
Myocytes were loaded with Fura-2 acetoxymethyl ester, Fura-2 AM (Molecular Probes 
Inc, Eugene, OR) as described previously [38].  Briefly, myocytes were incubated with 2 μM 
Fura 2 AM for 8 minutes at room temperature to load the indicator in the cytosol.  Myocytes 
were washed twice for 10 minutes with Tyrode’s solution containing 250 μM probenecid to retain 
the indicator in the cytosol.  A minimum of 30 min were allowed for de-esterification before 
imaging the cells.  Fura 2-AM loaded myocyte Ca transients recorded during 0.5 Hz field 
stimulation in 2 mM Ca Tyrode’s solution for 20 second at room temperature.  Then stimulation 
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was switched off followed by application of caffeine 10 mM for 5 seconds to estimate SR Ca 
content.  A subset of cells were exposed to 0Ca0Na Tyrode’s solution for 10 second then 
caffeine 10 mM applied for 30 second to estimate non-NCX Ca extrusion.  For each cell and 
each experimental condition, tau (τ), amplitude and baseline values were averaged from 3 
consecutive Ca transients. Ca transients were recorded and analyzed using commercially 
available data analysis software (IonOptix, IonWizardTM Milton, MA).  All experiments were 
conducted at room temperature. 
Western blot analysis 
Western blot analysis was carried out as in [39].  Briefly, hiPSC-CMs were seeded on 
mattress or non-mattress (1:60 Matrigel) for 5 days. hiPSC-CMs were lysed with RIPA buffer 
supplemented with protease inhibitor and phosphatase inhibitor cocktail (Sigma).  To remove 
excess Matrigel from mattress lysates, all lysates were centrifuged at 16,000 rpm for 15 minutes 
at 4°C.  Protein was quantified using Bio-Rad DC Protein Assay. 5 µg of protein lysates were 
resolved on 12 % mini-Protean TGX gels (Bio-rad) and transferred onto nitrocellulose 
membranes for immunoblotting.  Membranes were incubated with primary antibodies α-tubulin 
(rabbit monoclonal, Abcam), ssTnI (rabbit polyclonal, Sigma), cTnI (rabbit polyclonal, Abcam) 
overnight at 4°C. LI-COR. LI-COR secondary antibody were used and detected by Odyssey 
CLX (LI-COR) per manufacturer’s protocol. Protein band intensities were quantified and 
normalized to alpha-tubulin band intensities using Li-COR Image Studio software. 
Preparation of Matrigel mattress substrates 
Matrigel mattress platforms were prepared on the same day as CM dissociation and 
seeding.  Briefly, mattresses were arrayed on a glass coverslip (Corning) or Delta TPG Dish 
(Fisher Scientific).  Application of 1 μL lines of completely thawed, ice cold, undiluted growth 
factor-reduced Matrigel [8 - 12 mg/mL] (Corning) were arrayed in parallel. Matrigel was evenly 
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pipetted at a 45 degree angle (Figure 18) with a P2 pipet and corresponding 10 μL tip.  The 
mattresses were allowed to incubate for 8 - 10 minutes at room temperature at which point 200 
μL of RPMI 1640 medium, 2 % B-27 supplement (Invitrogen), and 1 % Pen-Strep (Life 
Technologies), with the addition of 40,000 CMs were immediately added, halting mattress 
polymerization.  Each mattress had a width of approximately 0.85 mm.  The thickness of each 
mattress was 0.40 - 0.88 mm and each line was approximately 23 mm long in detail below. 
Prepare before beginning mattress experiments: 
 24 hours before plating thaw Matrigel (Basement Membrane Matrix Growth Factor 
Reduced [8 - 12 mg/mL] (Corning Catalog # CB-40234)) aliquot on ice. 
 
Note: Typical aliquot is 250 uL of Matrigel in Eppendorf tube.  In case of time 
constraints Matrigel can be thawed based on manufactures recommendations (on 
ice ~ 1 hour until completely thawed).  
 
 Prepare P 2 pipet set at 1 uL 
 Prepare P 2 pipet tips (10 uL) 
 Prepare dishes ((Fisher Scientific Delta TPG DISH (50/Pack) 0.17mm black) / 
coverslip (Corning #12-542-C 25X25-1) for experiments (typically 3 dishes/coverslips 
per group) 
 M3 media (Cardiomyocyte (CM) media) RPMI 1640 with glucose (Invitrogen, cat# 
11875), B27 with insulin (Invitrogen, cat#17504-044) and 1 % Pen-Strep (Invitrogen, 
cat#17504-044). 
 TrypLE Express (Life Technologies) store at room temperature. 
 Timer 
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For cryopreserved hiPSC-CMs: 
1. Thaw day 30 – 35 cells using standard thawing protocol. Plate cells in 6 well Matrigel 
coated plates (1:200 diluted in DEM F12). Culture for 4 days to allow cell to recover from 
cryopreservation. Change M3 at 24 hours and 72 hours post thaw. 
2. Skip to dissociation and counting section 
For hiPSC-CMs already in culture: 
1. From standard small molecule based cardiac induction culture cells until day 30 – 35. 
2. Skip to dissociation and counting section 
Dissociation and counting 
1. Check status of cultured CMs before dissociation. Evaluate health of CMs make sure 
cells are viable and beating.  The purity of the population is very important some form of 
selection (e.g., metabolic selection or sorting) should be used to reduce experimental 
contamination of other cell types.  Non CMs may disrupt mattress substrate. 
2. Wash CMs with 2 ml per well D-PBS without CaCl2 or MgCl2 (Life Technologies). 
3. Remove D-PBS add 1 ml per well TrypLE Express (room temperature) incubate at 37 C 
for 15 minutes. 
4. Prepare 15 mL conical tube by adding 10 mL fresh M3. 
5. Use 5 mL serological pipette and pipettor to lift CMs by gently spraying 3 mL of fresh M3 
onto cells. 
6. Add the 4 mL (3mL fresh media + 1 mL TrypleE including and CMs) to the conical tube. 
7. Take one mL fresh M3 add to well and scrape cells to get any remaining CMs. 
8. Add the 1 mL M3 + CMs to the conical tube (Final volume 15 mL). 
9. Spin CMs for 5 minutes at 200g to pellet. 
10. Remove supernatant to 2 mL mark. 
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11. Re-suspend by adding 3 mL fresh M2 with 5 mL serological pipette and pipettor. To a 
final volume of 5 mL. 
12. Count cells using trypan blue in duplicate.  
13. Allow cells to remain at room temperature during mattress preparation process (10 
minutes). 
Matrigel mattress preparation: All steps carried out in tissue culture hood 
1. Mix Matrigel by flicking tube, immediately place back on ice. 
2. Start timer counting up, immediately before the first mattress is plated (time zero). 
3. Pipet 1uL Matigel up and down 3 times to chill pipet tip. 
4. Evenly pipette 1 uL undiluted Matrigel at 45 degree angle (Figure 18) onto 
dish/coverslip. Each 1 uL line is one mattress (4 lines or mattresses per dish/coverslip).  
Typically timing ~ 2 minutes to prepare 3 dish/coverslips or 12 mattresses. Plate all 
mattresses in the same orientation on each dish/coverslip; this will help when performing 
experiments at 40X. 
Note: Be sure to go the entire length of dish/coverslip ~ 23mm.  Short mattresses (10 
mm) will be too thick reducing mattress stability and may be outside the focal plane 
when viewing at 40X. Do not allow Matrigel to dry in pippet tip.  If this occurs quickly 
switch tips, pipette Matrigel up and down to chill tip and immediately continue.  Try to 
work quickly.  When starting out it is recommended to prepare a low number of plates (3) 
until proper timing is established, at which time you may scale up.  In addition practicing 
mattress preparation in advance is encouraged. 
Depending on imaging set up mattress near the edge of the dish/coverslip may be outside 
working area.  For this reason it is recommended to localize mattresses to the center of 
dish/coverslip. 
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5. Allow Mattress to incubate at room temperature for 8 – 10 minutes.  
 
Note: The timing is critical, incubation for longer than 10 minutes will result in stiff 
substrate and no shortening, incubation for shorter than 8 minutes will result in unstable 
mattress that may implode. 
 
6. Immediately plate CMs drop wise directly on mattress ~ 40,000 cells per dish in low 
volume ~ 200 uL in M3 with P1000 (Figure 18).  This will halt mattress polymerization. 
 
7. Allow cells to sit undisturbed at room temperature for 5 minutes.  This allows cell to 
adhere properly to mattress. 
 
Note: At this point visually inspect plates on microscope 5-20 X to ensure CMs are on 
the mattress and the density is appropriate (single cells).  If plates are too dense quickly 
make more mattress as above and plate fewer cells. 
 
8. Gently add 1 mL fresh M3 to each dish/coverslip. 
 
9. Place cells at 37 C for 5 days changing media daily. 
Note: visually inspect cells for correct morphology, immediately after plating cell should 
appear round (Figure 20), at ~ 24 hour post plating distinct morphological changes and 
small cell shortening may be observed.  By day 3 posts plating robust cell shortening 
should be observed. 
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Common mattress mistakes: 
1. High serum/FBS in media will result in networks of CMs no single cells (similar to 
endothelial cell assay). 
2. Preparing too many mattresses at one time. 
3. Plating CM or changing media harsh.  Gently change media from the edge of 
dish/coverslip as not to disrupt Mattresses. 
4. Plating CMs at high density.  For these experiments few cells are used, want to 
ensure cells are spread out for single cell analysis. 
5. Perfusion or suction to strong, this will tear cells off Mattress. 
6. Making Mattress to thick or thin. 
7. Not visually inspecting cells to confirm they are on mattresses. 
8. Preparing sloppy mattresses, while it is important to work quickly the integrity of each 
mattress is important. 
9. Plating too many Mattresses on a dish, it is important to be able to clearly distinguish 
between the mattress and the glass.  This is especially important for diseased CMs 
where contractile dysfunction may be a phenotype. 
10. Not using a timer. 
11. Culturing mattress cells to long. 14 days is the maximum it is recommended to 
perform experiments from 5 to 7 days. 
12. Not setting smoothness to 10 on IonWizard acquisition software (IonOptix) 
Measurement of cell volume 
Measurements of hiPSC-CM volume were obtained as previously descried [23], Z-stacks 
were obtained using a confocal microscope (LSM 510, 25X oil immersion Plan-Neofluar lens) as 
described.  Briefly, hiPSC-CMs were loaded with 5 µM Calcein AM (Molecular Probes, Eugene, 
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OR), for 30 min at room temperature; to label intracellular space.  HiPSC-CMs were washed 
twice to remove extracellular Calcein with no Ca Tyrode solution.  Fluorescence was excited at 
488-nm with 1% argon laser power. 25-46 images (1.5 µm sections) were obtained for each 
hiPSC-CM.  Images were reconstructed in three-dimensions and surface area and volume 
analyzed using the three-dimensional image analysis program IMARIS (Bitplane, South 
Windsor, CT).  
Immunohistochemistry 
Immunostaining of CMs was carried out as before [13].  Briefly, CMs were fixed in 2% 
paraformaldehyde for 5 minutes at room temperature, permeabilized with 0.2% Triton X-100 
(Sigma) for 10 minutes at 4 C. Samples were blocked with 1% BSA in PBS solution and 
incubated for 1 hour at room temperature.  Primary antibody, a-actinin (mouse monoclonal, 
Sigma), was added in 0.1% Triton X-100 1% BSA in PBS solution and incubated overnight at 4 
C.  Samples were washed with 0.2% Tween 20 in PBS, secondary antibodies specific to the 
primary IgG isotype were diluted (1:1000) in the same solution as the primary antibodies and 
incubated at room temperature for 1 hour.  Samples were washed with 0.2% Tween 20 in PBS 
twice and mounted.  Slides were examined with Olympus IX81 microscope coupled to 
Slidebook software.  For morphometric analysis images were imported into Image J and 
analyzed using standard plugins. 
Cardiac gene quantitative PCR screen 
A panel of cardiac genes was screened by qPCR.  Briefly, total RNA was isolated from 
Day 30-35 mattress and non-mattress hiPSC-CMs via TRIzol Reagent and Dnased treated via 
DNA-free DNA removal kit per manufacturer’s instructions (Ambion).  cDNA was generated                                                                                                                                                                                                                                                                                                                                                                                                   
using high-capacity cDNA reverse transcription Kit (Life Technologies). qPCR arrays were 
performed using Taqman ViiA7 Fast Real-Time RT-PCR System according to the 
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manufacturer’s instructions (Applied Biosystems, Foster City, CA, USA).  All TaqMan probes 
were obtained from Applied Biosystems (Table A-1).  Transcripts were normalized to 
housekeeping gene 18S rRNA and differential fold changes were presented as heat map. 
Action potential measurement 
Cardiac action potentials were measured from single cardiomyocytes with ruptured 
whole cell patch-clamp technique [40].  Briefly, cells were superfused with Tyrode’s solution 
containing (in mmol/L) 137 NaCl, 5.4 KCl, 10 HEPES, 10 Glucose, 1 MgCl2, 1.8 CaCl2; pH was 
adjusted to 7.4 with NaOH.  The glass pipette had access resistance of 3-6 MΩ after filling with 
the internal pipette solution containing (in mmol/L) 110 KCl, 5 Mg-ATP, 0.5 MgCl2, 5 EGTA, 10 
HEPES, pH adjusted to 7.2 with KOH.  Action potential was recorded using Axopatch 200B, 
Digidata 1322A and pClamp 8.0 software (Axon Instruments, Foster City, CA, USA) for data 
amplification and acquisition.  A 2ms current pulse at approximately 20% above threshold was 
provided to evoke action potentials at a cycle length of 2s (0.5Hz).   Electrophysiological data 
were analyzed using Clampfit 9.0 and the figures were prepared by using Origin 7.2.1.  All 
experiments were performed at room temperature. 
Measurements of sodium current 
Sodium currents (INa) were measured using external solution contained (in mmol/L): 135 
CsCl, 10 NaCl, 10 HEPES, 10 Glucose, 1.8 CaCl2, 1 MgCl2, pH 7.4 (CsOH).  To eliminate L- 
and T-type calcium currents, 1 µmol/L nisoldipine and 200 µmol/L NiCl2 were added to the 
external solution.  The internal pipette solution contained (in mmol/L): 5 NaCl, 135 CsCl, 5 
EGTA, 10 HEPES, 5 Mg-ATP, 2 CaCl2, pH 7.2 (CsOH). INa densities were measured by 
applying 40 - ms test pulse between -80mV and 60mV in 10mV increments from a holding 
potential of -120mV.  Steady-state inactivation was measured by varying the conditioning 
holding potential from -140 mV to -20mV, followed by a 40-ms test pulse to -20mV 
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Video based edge detection 
Video edge detection was used to assess cellular contraction (i.e., cell shortening) of 
contracting CMs.  Briefly; CMs were visualized using Nikon Ellipse T5100 coupled to IonOptix 
video microscopy system (IonOptix).  Spontaneous or field stimulated contraction traces were 
recorded in 2 mM Ca Tyrode solution.  For each cell and each experimental condition typical 
contraction parameters including percent cell shortening (i.e., percent of resting cell length) and 
contractile kinetics (i.e., time to peak 90% and time to baseline 90%) values were averaged. 
Contraction traces were recorded and analyzed using commercially available data analysis 
software (IonOptix, IonWizardTM Milton, MA).  Only isolated hiPSC-CMs with aspect ratio 
greater than or equal to 4 were used, non-shortening cells were excluded from analysis. 
Traction force microscopy 
Traction force maps were generated using the traction force microscopy method [39]. 
Briefly, contraction cycle of isolated hiPSC-CMs maintained on Matrigel mattress containing 
0.75 μm (Polysciences) fluorescence beads 1:50 were tracked by phase-contrast for contractile 
motion and fluorescence microscopy for substrate deformation; videos of individual hiPSC-CMs, 
cultured on mattress containing beads, were captured and particle image velocimetry (PIV) 
used to assess displacement deformation of hiPSC-CMs.  Fourier transform traction cytometry 
(FTTC) was used to access force using ImageJ plugin [19, 41].  For traction force microscopy 
experiments spontaneous beating hiPSC-CMs in 2 mM Ca Tyrode were evaluated at room 
temperature. 
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Contraction force and contraction stress measurements 
Contraction force and stress measurements were calculated based on the following 
equation. 
 
𝐹 =  (
𝐸Ao∆𝐿
𝐿𝑜
) 
Where, F is the force exerted on an object  
  E is the Young’s modulus (modulus of elasticity) of the substrate  
  A0 mean hiPSC-CM cross-sectional area 
  ΔL is the amount by which the length of the hiPSC-CM changes 
  L0 is the resting length of the hiPSC-CM 
 
Briefly, the resting cell length, L0, was determined by video based edge detection 
(IonOptix).  Mean modulus, E, of the Matrigel mattress, 5.8 kPa, was determined by Atomic 
Force Microscopy. ΔL, the change in cell length (i.e., peak cell shortening amplitude) of each 
cell was determined using video based edge detection (IonOptix).  The mean cross sectional 
area, A0, was calculated from Z stack images as described [23].  Assumptions for this analysis: 
as hiPSC-CMs shorten equal force is applied to the Matrigel mattress (i.e., that Matrigel 
mattress moves as CM contracts).  This is shown in our traction force analysis, by displacement 
of embedded florescent beads (Figure 26 A)  
Time-lapse microscopy 
Differential Interface Contrast (DIC) time lapse images were acquired using a Zeiss LSM 
Meta 710 confocal microscope.  Briefly, day 30 hiPSC-CMs were dissociated and re-plated on 
Matrigel mattress on MatTek 35mm petri dishes (P35G-1.5-14-C).  hiPSC-CMs were maintained 
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at 37° C with 5% CO2 and imaged every 15 minutes for 10 hours.  Images were exported into 
ImageJ for processing. 
Statistical analysis 
Data are mean ± SD unless indicate otherwise.  Statistical differences between two 
groups were tested with two-tailed Student’s t test.  Statistical differences among more than two 
groups were assessed using one-way ANOVA followed by tukey or bonferroni correction.  
Results were considered statistically significant if the p-value was less than 0.05. Statistical 
analysis was performed using Graphpad Prism 6. 
2.4 Results 
Elucidating the electrophysiological properties of single hiPSC-CM 
Single hiPSC-CMs were plated at low density on control substrate (<0.1 mm thick 1:60 
diluted matrigel, "control hiPSC-CM") and cell surface area, cell volume and EC coupling 
parameters (action potential and Ca handling) measured 3 – 7 days after plating.  We first 
measured CM shape and volume from Z-stacks of confocal images after loading cells with 
calcein to label intracellular space [26].  The shape of hiPSC-CM was highly variable, ranging 
from circular to elongated to triangular morphology (Figure 12 A).  HiPSC-CMs were smaller 
(cell volume 3.96 ± 0.25 pL, n = 44) compared to mouse ventricular CM (cell volume 29 ± 2 pL, 
n = 34).  On the other hand, cell surface area to volume ratio was significantly larger in hiPSC-
CMs compared to adult-CMs (Figure 12 B).  Circular hiPSC-CM had lower surface area and 
volume compared to elongated and triangular, but surface to volume ratio was not statistically 
different among the three control hiPSC-CM cell shapes (Figure 12 B). 
Electrophysiological properties have been the most studied parameters of hiPSC-CM EC 
coupling.  However, the majority of reports have not correlated results with adult-CM properties 
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under identical experimental conditions.  Therefore as a first step in characterizing the EC 
coupling of hiPSC-CMs; we assessed the electrophysiological properties including action 
potential and ion channels.  Despite the differences in cell size and shape, hiPSC-CM display 
relatively mature electrophysiological properties including amplitude, maximum diastolic 
potential and APD50/90 (Figure 13 and table 2) comparable to that of adult rabbit-CMs.  In 
addition hiPSC-CMs generated independently from multiple hiPSC lines exhibit robust L-type 
Ca currents that were not statistically different from L-type Ca current measured in mouse-CM 
(Figure. 14).  To the best of our knowledge this represents the first comparison of the 
electrophysiological properties of hiPSC-CMs and adult-CMs under identical experimental 
conditions. 
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Figure 12.  Surface area and volume of mouse-CMs and hiPSC-CMs.  A, representative 
examples of three-dimensional reconstruction of mouse-CM and hiPSC-CMs.  B, 
averaged data.  Data are mean ± SEM. N=13-34 per group.  ***P<0.001 vs mouse-CM. 
(Hwang, Kryshtal and Feaster et al., Journal of Molecular and Cellular Cardiology. 
2015; 85, 79-88). 
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Figure 13.  Electrophysiological characterization of hiPSC-CMs.  Representative action 
potential recordings of A, control hiPSC-CM and B, Rabbit-CM.  Dotted line indicates 0 mV.  C, 
Data are mean ± SEM n = 11 - 53 per group indicating relatively comparable 
electrophysiological properties as adult rabbit CMs.  ***P<0.001 vs mouse-CM.  Courtesy of Dr. 
Lili Wang. (Adapted from Feaster T. et al., Circulation Research 2015; doi: 
10.1161/CIRCRESAHA.115.307580). 
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Figure 14.  L-type Ca currents of hiPSC-CM and mouse-CM.  A, C, representative example of 
Ca currents from hiPSC-CM (Stanford, A) and mouse-CM B, Voltage protocol shown below 
current records. B, D current–voltage relationships of peak Ca currents from hiPSC-CM 
(Stanford (light gray), n=6; Vanderbilt (gray), n=6; Wisconsin, black, n=5) and from mouse CM 
(n=6), respectively.  Courtesy of Dr. Dmytro O. Kryshtal. (Hwang, Kryshtal and Feaster et al., 
Journal of Molecular and Cellular Cardiology. 2015; 85, 79-88). 
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Table 2.  Electrophysiological characterization.  Summary data are mean ± SEM.  *P<0.05 vs 
control . ***P<0.001 vs mouse-CM.  Courtesy of Dr. Lili Wang. (Feaster T. et al., Circulation 
Research 2015; doi: 10.1161/CIRCRESAHA.115.307580). 
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Elucidating the calcium handling properties of single hiPSC-CMs 
Although the cell shape and size of the nucleus of single hiPSC-CMs and adult mouse 
CMs differ drastically, staining with the low-affinity Ca sensitive indicator Mag Fluo-4 
demonstrates that both hiPSC-CMs and adult mouse-CMs have robust intracellular Ca stores 
(Figure 16 A).  We next compared the Ca handling of field-stimulated (0.5Hz) control hiPSC-
CMs generated independently from multiple hiPSC lines (i.e., Stanford University, Vanderbilt 
University and University of Wisconsin-Madison) to that of adult primary ventricular rabbit and 
mouse-CMs under identical experimental conditions using the ratiometric Ca indicator, Fura 2-
AM.  For these experiments frozen aliquots were shipped, recovered from cryopreservation, 
plated at low density on control substrate and compared 3–5 days after plating. 
Typical Ca handling parameters (diastolic [Ca], Ca transient amplitude, time to peak, Ca 
decay rate) (Figure 15 and 16 A) were not significantly different among all three hiPSC-CM 
lines.  Compared to adult rabbit and mouse CMs, only time to peak and Ca transient decay 
rates were significantly prolonged in hiPSC-CM, whereas all other Ca handling parameters were 
not different (Figure 16 C). 
We next tested for the presence of functional sarcoplasmic reticulum (SR) Ca stores 
using caffeine, an agonist of ryanodine receptor (RyR2) Ca release channels (Figure 16 B). 
Analogous to adult primary CMs, all hiPSC-CMs tested exhibited robust caffeine-releasable SR 
Ca stores (Figure 16 B and C).  Caffeine-induced Ca transients and hence SR Ca content were 
of similar magnitude and not significantly different from rabbit or mouse-CMs.  These results are 
consistent with the presence of intracellular Ca stores stained with Mag Fluo-4 (Figure 16 A) 
Taken together; these data demonstrate that single hiPSC-CMs exhibit intracellular Ca 
transients comparable to that of adult animal-CMs, and that the presence of functional SR in 
hiPSC-CMs derived using monolayer-based methods is consistent across multiple laboratories. 
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Figure 15.  Representative cytosolic calcium transients and typical parameters.  A, Twitch Ca 
transient parameters: Ca baseline (diastolic Ca), Ca transient amplitude (peak cytosolic Ca) and 
Ca decay (Ca removal from the cytoplasm, primarily by SERCA).  B, Caffeine Ca transient [10 
µM] parameters:  Caffeine transient amplitude (SR Ca content or SR Ca load) and caffeine Ca 
decay (Ca removal from the cytoplasm, primarily by NCX).  hiPSC-CMs loaded with Fura 2-AM 
[2 µM]. 
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Figure 16.  Ca handling of hiPSC-CMs and animal CMs.  A, confocal images of a mouse-CMs 
and hiPSC-CMs loaded with low-affinity Ca indicator, Mag-Fluo-4AM 5μM to label intracellular 
Ca stores (i.e. SR).  B-C, representative Ca transients B and averaged data C recorded in 
hiPSC-CMs and acutely isolated adult ventricular rabbit and mouse CMs.  Cells were field-
stimulated (0.5Hz, 20s train) in 2mM Ca Tyrode's solution followed by caffeine spritz (10mM, 5s) 
to estimate SR Ca content.  Data are mean ± SEM.  N=22-27 per group.  *P<0.05 vs. hiPSC-
CM.  (hiPSC-CM images A and example Ca transient records B shown are from Vanderbilt 
hiPSC-CMs).  Courtesy of Dr. Hyun Hwang.  (Hwang, Kryshtal and Feaster et al., Journal of 
Molecular and Cellular Cardiology 2015; 85, 79-88). 
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Development of an in vitro method to assess contractility of hiPSC-CMs 
 
The matrigel mattress method 
Current methods to evaluate cellular contractile properties of individual hiPSC-CMs are 
lacking.  For this reason, many laboratories have moved to multicellular preparations such as 
2D monolayer (e.g., XCELLigence) [42] or 3D multicellular (e.g., EHT).  While useful, these 
methods make detailed hiPSC-CM contraction studies challenging for most laboratories.  
For single hiPSC-CMs studies hiPSC-CMs are routinely plated on tissue culture 
substrates such as gelatin or Matrigel (<0.1 mm thick 1:60 diluted matrigel, "control hiPSC-
CMs") a commercially available extracellular matrix (ECM) preparation, (Figure 17 A and Figure 
18 A) [33].  However, such substrates do not enable detailed assessment of contractile 
properties as the majorly of the cells are circular displaying unaligned myofilaments (Figure 17) 
with no relevant shortening (i.e., little or no contractile work) [11][18].  As such methods 
including atomic force microscopy (AFM), traction force microscopy (TFM) and image-based 
rhythmic methods have been used [19] (Figure 17 B - D).  As discussed earlier these methods 
have their limitations. 
I sought to develop a simple, rapid, low-cost contractility platform, which would enable 
robust reproducible hiPSC-CM cell shortening and hence evaluation of contraction performance.  
I report the Matrigel mattress method [24] for routine evaluation of contractile performance 
(Figure 18).  I hypothesized that, provided a substrate with appropriate properties such as 
stiffness and composition, hiPSC-CMs would shorten as is commonly observed with acutely 
isolated adult animal-CMs.  Hence, enabling contractile assessment with standardized 
equipment typically used for adult-CMs.  A broad substrate screen [39] revealed that undiluted 
Matrigel (0.4 - 0.8 mm thick, “mattress hiPSC-CMs”), which we have termed the Matrigel 
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mattress, supported elongation, alignment and robust hiPSC-CM shortening (Figure 19 A).  For 
these experiments day 30 - 35 hiPSC-CMs were dissociated and re-plated on either control or 
mattress (Figure 19 A and D) and evaluated 5 - 7 days after plating.  We took advantage of the 
inherent properties of Matrigel, its substrate modulus and its ability to adhere cells without 
additional functionalization [43]. 
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Figure 17.  Current single hiPSC-CM contractility assays.  A, Typical control hiPSC-CMs 
morphology (i.e., Matrigel diluted 1:60 in DMEM F12).  Scale bar, 25 µm.  B, Schematic of 
atomic force microscopy set up.  (Liu J. et al., PLoS. 2012; doi: 10.1371/journal.pone.0037559).  
C, Representative traction force microscopy and analysis and D, image-based pixel analysis. 
(Panels C and D adapted from, Hayakawa T. et al., Journal of Molecular and Cellular 
Cardiology. 2014; 77:178-91).  Representative hiPSC-CM image A is from Vanderbilt University, 
derived from hiPSC line CC2). 
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Figure 18.  Overview of Matrigel mattress method. A, Schematic of cardiac induction and 
Matrigel mattress method plating protocol.  B, Matrigel mattress method work flow.  C, Matrigel 
mattresses plated on Delta TPG Dish (Fisher Scientific), white arrows indicate edge of each 
mattress, blue dye included to visualize mattress.  D, hiPSC-CMs plated on control (left panel) 
and mattress (right panel).  Scale bar 50 µm.  White arrows indicate edge of mattress platform. 
(Feaster T. et al., Circulation Research 2015; doi: 10.1161/CIRCRESAHA.115.307580). 
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Figure 19.  Matrigel mattress morphometry.  A, Immunofluorescence staining of cardiomyocyte 
(CM) structural marker α-actinin (green) and nucleus (blue, DAPI) for control human induced 
pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) (left), mattress  hiPSC-CM (center) 
and rabbit-CM (right).  Scale bar 20 µm.  63X.  B, Cell morphometry measuring circularity index 
(left) and sarcomere length (right) are plotted for indicated CMs.  C, Surface area (left), cell 
volume (center) and surface area to volume ratio (right) are plotted.  Data are mean ± SEM. (n = 
9 – 48 cells per group).  *P<0.05 vs control.  (Feaster T. et al., Circulation Research 2015; doi: 
10.1161/CIRCRESAHA.115.307580). 
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Mattress hiPSC-CMs display aligned myofilaments  
Modulation of substrate stiffness has been shown to effect CM morphology [19].  Current 
cardiac induction strategies generate hiPSC-CMs, of similar age (i.e., day 30), with relatively 
immature structure exhibiting circular shape and unaligned myofilament architecture.  I 
assessed morphology of mattress hiPSC-CMs using quantitative immunofluorescence staining 
(Figure 19 A and B) and Z stacks of confocal images (Figure 19 C).  First, CMs were 
immunostained with α-actinin, Z-disk protein and dapi, nuclear marker.  I found that mattress 
hiPSC-CMs display hallmarks of adult CMs that were missing in control hiPSC-CMs.  Mattress 
hiPSC-CMs were more elongated, with increased anisotropy and aspect ratio, calculated as the 
length of the long axis divided by the length of the short axis [19] [20] and decreased circularity 
[11] (Figure 19 B) relative to control hiPSC-CMs.  In addition, mattress hiPSC-CMs display 
increased sarcomere length more comparable to that of freshly isolated adult ventricular-CMs 
(Figure 19 B) and increased surface area.  However, there was no change observed in cell 
volume which confirmed a quantitative geometric transition for mattress hiPSC-CMs, as shown 
in time-lapse images (Figure 20), along with increased surface area to volume ratio (Figure 19 
C).  These data demonstrate that while the Matrigel mattress does not enhance hiPSC-CM size 
it does enhance key morphological characteristics of hiPSC-CMs.  In addition to the significant 
differences in morphology, I discovered that mattress hiPSC-CMs display visible cellular 
contraction (i.e., cell shortening) relative to control hiPSC-CMs (Figure 21) as demonstrated by 
percent of single hiPSC-CMs visibly shortening. 
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Figure 20.  Sequential montage of hiPSC-CMs on Matrigel mattress.  Scale bar 20 µm.  Day 30 
hiPSC-CMs were plated on Matrigel mattress and imaged every 15 minutes for 10 hours. White 
arrow indicates edge of Matrigel mattress.  Images show mattress hiPSC-CM elongating in 
culture.  Courtesy of Mr. Adrian C Gadar.  (Feaster T. et al., Circulation Research 2015; doi: 
10.1161/CIRCRESAHA.115.307580). 
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Figure 21.  Robust shortening of Mattress hiPSC-CMs.  Percent of hiPSC-CMs shortening on 
control substrate (i.e., Matrigel 1:60 and Matrigel mattress) cells are non-paced.  *P < 0.0001 vs 
control.  N = 407 – 547 per group.  (Adapted from Feaster T. et al., Circulation Research 2015; 
doi: 10.1161/CIRCRESAHA.115.307580). 
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Mattress calcium handling assessment 
To elucidate the mechanisms responsible for difference in contractile performance, I 
evaluated intracellular Ca handling, as Ca is directly upstream of contraction.  I found that 
typical twitch Ca handling parameters (i.e., baseline, amplitude, decay) (Figure 22) were not 
significantly different in both groups suggesting changes in global Ca are not responsible for 
increased contractile performance (Figure 22 A and Table 3) of mattress hiPSC-CMs. However 
there was a significant increase in maximum return velocity of mattress hiPSC-CM twitch Ca 
transient which suggests enhanced EC coupling.  Next, I evaluated the contribution of 
sarcoplasmic reticulum (SR) Ca stores using caffeine, an agonist of ryanodine receptor (RyR2) 
Ca release channels.  Analogous to control, mattress hiPSC-CMs exhibited robust caffeine-
releasable SR Ca stores (Figure 22 B and Table 3).  Both caffeine-induced Ca transients and 
hence SR Ca content were of similar magnitude and not significantly different in both groups. 
However, the caffeine-induced Ca decay rate was faster in mattress hiPSC-CMs, which largely 
represents enhanced sodium calcium exchanger (NCX) activity.  Taken together, these results 
are consistent with negligible effect of the Matrigel mattress on intracellular twitch Ca handling. 
The result that hiPSC-CMs maintained on Matrigel mattress exhibit robust cellular shortening 
and have comparable twitch Ca handling as control hiPSC-CMs suggest that the mattress does 
not negatively affect Ca handling properties.  Further, these data suggest that Ca handling 
differences are not the primary mechanism responsible for the enhanced contractile 
performance and suggest that other interactions (e.g., substrate stiffness, integrins or 
myofilament alignment) are responsible. 
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Figure 22.  Mattress hiPSC-CM Ca handling.  A, Representative Control (Black) and Mattress 
(Grey) hiPSC-CM Twitch Calcium transient.  B, Representative Control (Black) and Mattress 
(Grey) hiPSC-CM Caffeine [10mM] Calcium transient.  C, Data are mean ± SEM. N=25-35 per 
group.  Date indicate negligible effect of the mattress culture method on twitch Ca handling.  
(Adapted from Feaster T. et al., Circulation Research 2015; doi: 
10.1161/CIRCRESAHA.115.307580). 
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Table 3.  Mattress Ca handling properties (non-paced).  Summary data are mean ± SEM.  
*P<0.05 vs control.  (Feaster T. et al., Circulation Research  2015; doi: 
10.1161/CIRCRESAHA.115.307580). 
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Elucidating the contractile properties of single hiPSC-CMs 
 
Robust cellular shortening of isolated hiPSC-CMs  
hiPSC-CM contractile properties have not been well described, greatly limiting our 
understanding of EC coupling.  Hence, I set out to elucidate the baseline contractile properties 
(i.e., contraction, rates and kinetics) (Figure 23), of day 30 - 35 hiPSC-CMs, using the novel 
culture method.  When quantitated with video-based microscopy, un-paced, mattress hiPSC-
CMs contracted ~9.0 % of their resting cell length as compared to ~ 0.4 % for control (Figure 24 
and Table 4).  For comparison, contractions of this magnitude have only been reported for late-
stage hiPSC-CMs after 80-120 days in culture [21], suggesting the mattress method accelerates 
this process, thus validating the significant contribution of the Matrigel mattress method to 
assessment of early hiPSC-CM contractility in vitro and demonstrates significant improvement 
over standard conditions. 
As there is an expected inherent variability in hiPSC-CMs studies I evaluated the 
reproducibility of hiPSC-CMs contractile properties.  To do this I quantified cellular contraction 
parameters of hiPSC-CMs independently generated at a different institution from an 
independently generated hiPSC line (Figure 24 and Table 4) as well as post recovery from 
cryopreservation.  I found that all hiPSC-CMs plated on the mattress have comparable 
contractile properties including kinetics and beat frequency (Figure 24 and Table 4).  These 
results demonstrate that mattress hiPSC-CM cellular contractile measurements are consistent 
and reproducible across lines.  
The result that mattress hiPSC-CMs exhibit robust cellular shortening relative to control 
hiPSC-CMs suggest that the Matrigel mattress enables detailed quantifiable cell shortening, 
using standard microscopy techniques commonly used to assess adult-CMs.  As such 
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implementation of the Matrigel mattress provides a robust platform for simultaneous evaluation 
of cellular contractile properties and other functional readouts including Ca handling of single 
hiPSC-CMs. 
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Figure 23.  Diagram of typical cell shortening parameters:  Resting cell length (cell length during 
diastole), peak cell shortening (cell length when maximally contracted, during systole), % cell 
shortening (cellular contraction normalized to the resting cell length) and contraction and 
relaxation kinetics (time to peak and time to baseline, respectively). 
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Figure 24.  Matrigel mattress cell shortening measurements.  A, Representative non-mattress 
and B, mattress hiPSC-CM contraction traces.  C, Data are mean ± SEM.  N=6-17 per group.  
Data indicate robust quantifiable contractile properties of mattress hiPSC-CMs.  *P < 0.05  vs 
control.  Spontaneously beating hiPSC-CMs.  Control hiPSC-CM contraction and relaxation 
kinetics were not measureable.  (Adapted from Feaster T. et al., Circulation Research 2015; doi: 
10.1161/CIRCRESAHA.115.307580). 
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Table 4.  hiPSC-CM contractile properties.  Summary data are mean ± SEM  *P < 0.05 vs 
control.  (Feaster T. et al., Circulation Research 2015; doi: 
10.1161/CIRCRESAHA.115.307580). 
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Mattress hiPSC-CMs display mature contractile properties 
It remains unclear whether hiPSC-CMs accurately recapitulate characteristics of native-
CMs.  Therefore I directly compared contractile properties of hiPSC-CMs to that of freshly 
isolated adult ventricular CMs (i.e., rabbit and mouse) under identical experimental conditions 
(Figure 25).  To determine the physiological relevance and provide context for the hiPSC-CM 
contractile properties, field-stimulated (0.2Hz) hiPSC-CMs and adult rabbit and mouse 
ventricular CMs were evaluated.  While hiPSC-CMs were significantly shorter than adult-CMs 
(Figure 25 B left panel), consistent with the morphometric assessment.  Cellular contraction and 
peak shortening amplitude (data not shown) were not significantly different and of similar 
magnitude among groups (Figure 25 B right panel).  I also discovered mattress hiPSC-CMs 
exhibit contractile kinetics (i.e., time to peak and time to baseline) more comparable to that of 
rabbit-CMs (Figure 25 C), which are thought to be more comparable to human CMs [2], and 
significantly slower compared to that of mouse-CMs.  These data suggest hiPSC-CMs are 
capable of producing cellular contractions and kinetics comparable to adult-CMs, displaying 
mature cellular contraction in vitro. 
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Figure 25.  hiPSC-CM and adult-CM contractile comparison.  A, Representative contraction 
traces of indicated CMs, 0.2Hz.  B, and C, data are mean ± SEM.  N = 6 – 20 cells per group.  
Data indicate mattress hiPSC-CMs display comparable contractile properties as adult rabbit-
CMs.  **** P< 0.0001 vs hiPSC-CM.  *P<0.05 vs mouse-CM.  n.s, Not significant.  (Feaster T. et 
al., Circulation Research 2015; doi: 10.1161/CIRCRESAHA.115.307580). 
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Contraction force and traction force of hiPSC-CMs 
CM force is decreased in end-stage HF as such methods to evaluate and modulate this 
parameter are sought after.  Here, I set out to determine if the contraction force produced by 
mattress hiPSC-CMs could be obtain from the Matrigel mattress platform analysis.  HiPSC-CM 
contraction force was calculated based on the area of each hiPSC-CM, the deflection (i.e., peak 
shortening amplitude) and the mean modulus of the Matrigel mattress platform.  To account for 
differences in cell size and enable experimental comparison, total force was normalized to cross 
sectional area and is presented as (mN/mm2).  I found the average contraction force of hiPSC-
CMs to be 0.3 ± 0.1 mN/mm2  (Figure 26).  
Next, we evaluated how well the Matrigel mattress force compared with the established 
traction force microscopy (TFM) method (Figure 26 A and B) [7, 10] we found Matrigel mattress 
force correlated well with the established TFM method, exhibiting a positive correlation.  These 
results demonstrate that hiPSC-CMs contraction forces can be evaluated with the data obtain 
from the Matrigel mattress platform. 
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Figure 26.  Traction Force correlation.  A, Phase contrast image of hiPSC-CMs on Matrigel 
mattress with embedded fluorescence beads (0.75 µm diameter).  B, Fluorescent image of A, C. 
Representative displacement field image of fluorescent beads calculated with particle image 
velocimetry (PIV) algorithm.  D, Fourier transform traction cytometry (FTTC). (A – D ).  Scale 
bar, 20 µm.  E, Correlation between Matrigel mattress platform calculated contraction stress and 
traction force estimated with the FTTC algorithm (n = 15 cells).  Courtesy of Mr. Charles H. 
Williams. (Feaster T. et al., Circulation Research 2015; doi: 
10.1161/CIRCRESAHA.115.307580). 
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Enhanced maturation of hiPSC-CMs 
 
Cardiac molecular profile of mattress hiPSC-CMs 
In an attempt to correlate functional differences of mattress hiPSC-CMs with molecular 
expression and to provide mechanistic insight, we performed transcriptional profiling of a subset 
of cardiac genes involved in EC coupling (Figure 27 A).  We observed differential expression of 
genes including TNNI3, encoding cardiac troponin I.  Cardiac troponin I is minimally expressed 
in hiPSC-CMs on standard substrates.  However, it is required for a mature molecular signature 
[25].  Western blot analysis confirmed transcriptional alteration associated with the mattress 
(Figure 27 B and C), and thus, we have validated the ability of the Matrigel mattress to modulate 
not only hiPSC-CM morphology and contractility but also underlying molecular profile.  
Enhanced electrophysiological properties of hiPSC-CMs 
To determine if the Matrigel mattress enhances electrophysiological properties we evaluated 
action potential morphology and sodium current density of mattress and control hiPSC-CMs. 
(Figure 28).  We found mattress hiPSC-CMs have increased upstroke velocity (84 ± 8.0 V/s P < 
0.05) relative to control hiPSC-CMs, consistent with both increased sodium current density 
(Figure 28 B and C) and increased SCN5A transcript (Figure 27 A).  
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Figure 27.  Mattress hiPSC-CM molecular characterization.  A, Heat map from gene expression 
screen, non-mattress and mattress hiPSC-CMs, measured by real-time qPCR.  Low expression 
(Black) and high expression (Yellow).  B, Western blot confirmation for indicated proteins (n = 2 
independent biological replicates).  C, Summary bar graphs of relative ssTnI and cTnI 
expression, data are mean ± SEM.  Courtesy of Mr. Adrian C Gadar.  (Feaster T. et al., 
Circulation Research 2015; doi: 10.1161/CIRCRESAHA.115.307580). 
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Figure 28. Characteristics of mattress sodium (I
Na
) current. A, Representative I
Na 
current of 
control hiPSC-CMs and B, mattress hiPSC-CMs. Traces were elicited be voltage protocol 
shown below current recording. C, Current-voltage relationship of peak I
Na 
current from control 
hiPSC-CMs and Mattress hiPSC-CMs. D, I
Na
 Steady-state inactivation for control hiPSC-CMs 
and mattress (hiPSC-CMs). (Control hiPSC-CMs, black, n = 13) and (mattress hiPSC-CMs, 
grey, n = 15). V
1/2
, half activation voltage. Courtesy of Dr. Lili Wang. (Feaster T. et al., 
Circulation Research 2015; doi: 10.1161/CIRCRESAHA.115.307580). 
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2.5 Discussion 
hiPSC-CMs could become a powerful tool for basic biology and drug discovery. 
However, for the full potential of this technology to be realized, detailed characterization of EC 
coupling is required.  This includes multiple functional read outs (i.e., electrophysiology, Ca 
handling and contractility) under identical experimental conditions however this is rarely done. I 
systematically evaluate key aspects of EC coupling properties of hiPSC-CMs, at the single cell 
level.  
Major new findings are that hiPSC-CMs generated by the latest monolayer based 
cardiac differentiation protocols display relatively mature electrophysiological properties (Figure 
13).  Along with robust and functional SR Ca handling that is not statistically different from that 
of acutely-isolated adult rabbit ventricular CMs (Figure 16), a species that is generally thought to 
exhibit cardiac Ca handling similar to humans [3].  We further demonstrate that independently 
generated hiPSC-CM lines from healthy donors exhibit comparable and reproducible Ca 
handling.  In addition the establishment and implementation of our novel culture method enables 
robust hiPSC-CM cellular shortening of single hiPSC-CMs (Figure 21).  I demonstrate hiPSC-
CM exhibit relatively mature contractile properties that are comparable to adult rabbit-CMs and 
reproducible across laboratories (Figure 24 and 25).  Moreover, the mattress platform enhances 
maturation of hiPSC-CMs including morphology, molecular expression and action potential 
waveform. 
Comparison of hiPSC-CMs and acutely-isolated adult CMs EC coupling.  
Lacking access to acutely-isolated healthy human ventricular CMs – a common problem 
for the field – we compared hiPSC-CMs with adult rabbit and mouse CMs.  Rabbit-CMs have 
been widely used to model human heart diseases [3].  We found that hiPSC-CMs have twitch 
EC coupling properties comparable to that of rabbit-CMs.  This includes Ca transient 
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amplitude, % cell shortening and action potential amplitude.  This is in direct contrasts with 
previous reports indicating that hiPSC-CMs have smaller relatively “immature” 
electrophysiology, Ca handling and contractile properties [28] [22].  On the other hand there are 
several EC coupling differences between hiPSC-CM and adult rabbit-CMs.  For instance there 
are electrophysiological differences such as significantly slower upstroke velocity (Figure 13 and 
table 2).  This could be the result of decreased INa relative to rabbit-CMs.  HiPSC-CMs also 
display markedly smaller cell capacitance (Figure 13 C) consistent with previous reports [11] 
and our morphometric analysis (Figure 12) of their cell size.  This may be the result of the 
perceived unloaded culture conditions.  As for Ca handling we observed differences between 
hiPSC-CM and rabbit CM including: significantly slower SERCA and NCX Ca transport (Table 3) 
slower time to peak Ca transient (Figure 16).  Morphological factors such as the lack of t-tubules 
of hiPSC-CMs leading to an inefficient Ca induced Ca release and hence impaired Ca-
dependent inhibition of L-type Ca current during the action potential plateau may contribute to 
the slower time to peak of hiPSC-CM Ca transients.  While the differences in SERCA and NCX 
function could be due to species differences between human and rabbits, a more likely 
explanation is that Ca transport remains somewhat immature in hiPSC-CMs compared to adult 
CMs.  
With respect to contractile properties despite the fact that hiPSC-CMs display 
significantly shorter resting cell length they are capable of producing contractions comparable to 
adult-CMs (Figure 25).  Moreover, their contractile kinetics are comparable to those of adult 
rabbit-CMs.  Thus, I provided the first direct comparison of isolated hiPSC-CM contractile 
properties and adult-CMs, a comparison that has been lacking in the field.  In addition the direct 
comparison to freshly isolated adult-CMs studied under identical experimental conditions further 
demonstrates the utility of this platform.  
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Advantages of the matrigel mattress culture method 
The culture method we describe here has a number of significant advantages: (1) the 
commercial availably of Matrigel, (2) the simple logistics of the Matrigel mattress platform 
preparation, (3) the noninvasive and non-lethal nature of the experiments which widens the 
scope of potential studies, (4) the mattress is label free this is particular important for Ca 
handling experiments enabling multiple fluorophores to be used simultaneously without 
substrate interference, (i.e., embedded fluorescent beads), as is the case with traction force 
microcopy,  (5) this platform does not require functionalization as Matrigel provides an inherent 
adhesive substrate for attachment unlike other hydrogel based platform (e.g., polyacrimide),  (6) 
the moduli of Matrigel mattress used in this study, ~ 5.8 kPa, is physiologically relevant 
recapitulating cardiac tissues which provide stiffness of 4.0 to 46.2 kPa [12][41] this in contrast 
to the perceived preload of glass (i.e., GPa range) [44].  Taken together these advantages 
demonstrate how the proposed platform will prove useful by making cellular mechanical 
measurements translatable to most laboratories.  
Implications for future hiPSC studies 
The results of our experiments have a number of implications for using hiPSC-CMs as 
experimental models.  First, monolayer-based methods of cardiac differentiation are capable of 
generating hiPSC-CM with robust and functional SR Ca stores.  In addition the mattress method 
enables quantifiable and robust cell shortening.  The results presented here provide a 
foundation for future disease modeling studies by elucidating “healthy” hiPSC-CM EC coupling 
properties.  In this method hiPSC-CMs can be recovered from cryopreservation demonstrating 
that these cells exhibit robust reproducible properties.  And culturing hiPSC-CMs on mattress 
enhances key characteristics of maturation.  Moreover, as there is limited contractile movement 
on standard substrates the Matrigel mattress may be able to systematically unmask disease 
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phenotypes not present under standard culture conditions [18].   And hiPSC-CMs made from 
different hiPSC lines that were derived from different somatic tissue sources by different 
methods of reprogramming have comparable Ca handling and contractile properties.  This result 
is reassuring, since there is concern in the field that starting cell source (e.g. neonatal or adult 
fibroblast) and reprogramming methodology (e.g. integrating or non-integrating) may impact 
differentiated cell progeny (e.g., alter EC coupling) our results demonstrate starting somatic cell 
source does not clearly impact E-C coupling functional readouts. 
Finally, the methods of cryopreservation and recovery described here could serve as a 
first step of standardization, which is greatly needed in the field.  Having frozen stocks of hiPSC-
CMs that can be reproducibly recovered, as shown here, opens up a number of possibilities.  
Cells can be shared between laboratories, saved for future experiments, or for doing larger 
experiments such as screening compound libraries and regenerative medicine. 
Limitations 
There are several limitations for the Ca handling comparison.  To ensure identical study 
conditions, all hiPSC-CMs were frozen at specific dates after cardiac differentiation, then 
thawed and re-plated prior to study.  We cannot exclude that the freezing and thawing process 
has altered the phenotype of the hiPSC-CMs.  However, the advantage of this approach is that 
multiple batches of re-plated cells from different labs can be readily compared, which is why we 
chose this approach here.  This is also the reason why we could not examine hiPSC-CMs older 
than 30 days, because the viability of older cells decreases substantially after freezing.  Another 
limitation is that we did not differentiate hiPSC-CM subtype (i.e., nodal, atrial, and ventricular-
like).  However, previous studies have shown that the cardiac induction protocols used here 
produce approximately 80% ventricular-like CMs.  Importantly, the cell to cell variability of Ca 
handling parameters (i.e., twitch transient amplitude) of hiPSC-CMs was comparable to that of 
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acutely-isolated adult CMs (approximately a 30% coefficient of variation).  As such methods to 
enrich for a desired subtype will be useful, to characterize the chamber specific properties of 
hiPSC-CMs and for chamber specific diseases such as atrial fibrillation 
In addition there are several limitations to our hiPSC-CM contractility studies, most 
notably hiPSC-CM maturity.  The immature phenotype, relative to adult primary CMs, is based 
on several structural and functional endpoints, previously reported.  Here we report external 
factors, namely substrate stiffness, can enhance hiPSC-CM morphometry.  Further work will 
need to be done to fully understand these mechanisms, currently may researchers are exploring 
additional methods including, biochemical and electrical stimulation, to accelerate hiPSC-CM 
maturation in vitro. 
While unlikely, the dependence on Matrigel, a chemically undefined substrate, may be a 
limitation.  Whereas Matrigel is routinely used for hiPSC maintenance and hiPSC-CM functional 
studies, there may be unknown effects of undiluted Matrigel on contractile properties.  For this 
reason we and others are working to develop chemically define substrates.  If these substrates 
are capable of capturing contractile properties of isolated hiPSC-CMs they will be a nice 
addition to this approach. 
Here, our major findings focus on cellular contractility (i.e., cell shortening), instead of 
sarcomere length.  While sarcomere length can also be measured with the Matrigel mattress 
platform we focused on changes in total cell length.  It has previously been demonstrated that 
changes in hPSC-CM cell length and sarcomere length correlate well with each other [21].  
Additionally, the limited throughput of the Matrigel mattress platform makes large scale primary 
screening assays unrealistic.  While in the future the Matrigel mattress may be extend to 
medium throughput, in its current form it will prove useful as a secondary screening assay, early 
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in candidate identification, providing mechanistic insight in a human background. Indeed, we are 
currently developing such high throughput format.  
I also present a calculated contraction force measurement.  This mathematically derived 
contraction force is not a direct measurement and does not represent an absolute 
measurement.  The contraction force presented takes into account the area of each hiPSC-CM 
making it possible to compare results across laboratories.  However, it should be noted that 
edge detection is a two point analysis based on lateral movement that may underestimate total 
force produced as axial modes of force may not be accounted for.  Additionally the cross 
sectional area used only applies to hiPSC-CMs in this study and age.  
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Chapter 3 
hiPSC-CM DISEASE MODELING 
3.1 Chapter Abstract 
Sarcomeric cardiomyopathy, encompassing hypertrophic cardiomyopathy (HCM), dilated 
cardiomyopathy (DCM), and restrictive cardiomyopathy (RCM), is an important cause of 
morbidity and mortality.  While human genetic studies have provided lists of causal sarcomeric 
gene mutations, the pathobiology of human sarcomeric cardiomyopathies remain generally 
poorly understood.  A major hindrance to detailed study of sarcomeric cardiomyopathies in 
humans has been lack of an appropriate in vitro cardiac tissue models.  Here, I use hiPSC-CM 
technology to study the functional consequence of sarcomeric cardiomyopathies specifically Ca 
handling and contractility.  HiPSC-CMs were generated through reprogramming of somatic cells 
of two cardiomyopathy patients, one carrying a HCM MYH7 R633H mutation and one with DCM 
but no known mutation.  In addition I use genetic engineering strategies to evaluate the RCM 
TNNI3 R204C mutation.  I found HCM MYH7 R633H hiPSC-CMs display abnormal twitch Ca 
handling properties including significantly slower Ca decay rates and prolonged Ca handling 
kinetics (i.e., time to peak and time to baseline) concurrent with contractile dysfunction and I 
provided evidence supporting an enhanced myofilament Ca sensitivity mechanism.  Next, I 
recapitulate in vitro DCM phenotypes, in a novel DCM hiPSC-CM line, including myofilament 
disarray, altered Ca handling kinetic and increased SR Ca content.  Finally I provide a reagent to 
evaluate the novel RCM cardiac troponin I mutation.  I conclude that patient specific hiPSC-CMs 
exhibit classic clinical phenotypes, and that the implementation of the mattress platform 
facilitates elucidation of previously undiscovered defects of diseased hiPSC-CM.  
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3.2 Introduction 
The lack of human heart samples has been a major barrier to detailed understanding of 
the pathophysiology of human cardiomyopathies.  However, this spectrum of diseases is 
thought to be multifactorial, primarily involving complex interplay between genetic sarcomere 
mutations and acquired events or compensatory mechanisms.  As such typical disease 
progression involves maladaptive phenotypic alterations in myocardial structure and function.  
Despite the depth of knowledge, surrounding the genetic association little is known of the 
pathophysiology and underling mechanisms of cardiomyopathies. 
To study heart failure pathology and pathophysiology I use hiPSC-CMs, as an intact 
human heart cell model.  Through collaboration with the Vanderbilt Center for Inherited Heart 
Disease I have obtained dozens of explanted cardiac tissue samples to generate hiPSC lines.  
We have also collaborated with other institutions to obtain diseased hiPSC-CMs carrying 
specific mutations.  
Here, I study the hypertrophic cardiomyopathy (HCM) line, SCVI6-CM, derived at 
Stanford University (Joseph Wu Laboratory) from a patient carrying an autosomal dominant 
missense mutation Arg663His in the gene MYH7 which encodes the sarcomere component β-
myosin heavy chain.  Patients with this disease causing mutation present with abnormal 
thickening of the heart muscle and progress to a HF phenotype.  Lan and colleagues showed 
HCM hiPSC-CMs display key structural features of HCM such as cellular hypertrophy and 
increased multinucleation [13]. HCM hiPSC-CMs displayed key functional features such as 
contractile arrhythmias evaluated by pixel quantification analysis (as disused above), and Ca 
handling abnormalities such as increased diastolic Ca and decreased SR Ca content however 
no change was reported in Ca handling decay rate or kinetics.  Detailed assessment of 
contractile properties was not performed due to current methodological limitation. 
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Dilated cardiomyopathy (DCM) is the most common form of cardiomyopathy.  Here we 
derived hiPSC from a DCM patient (6 months old) by plasmid-based reprogramming from left 
ventricular cardiac fibroblasts.  Genetic testing of a panel of cardiomyopathy associated genes 
revealed no known mutation.  Sun and colleagues demonstrated DCM hiPSC-CMs derived form 
a patient carrying TNNT2 mutation, which encodes cardiac troponin T, recapitulate DCM 
phenotypes in vitro such as disorganized myofilaments, Ca handling abnormalities and using 
AFM show mechanical dysfunction [12]. 
Restrictive cardiomyopathy (RCM) is the most devastating form of cardiomyopathy with 
a high risk of disease progression and death for which there are few animal models and no 
hiPSC-CMs model to date.  While mutations in the desmin, α-cardiac actin, cardiac troponin T 
and cardiac troponin I (TNNI3) genes have been associated with RCM, how  specific mutations 
alter human cardiomyocyte (CM) structure and function, and ultimately cause the RCM 
phenotype, are largely unknown. 
I identified a RCM patient with a de novo R204C mutation in TNNI3, which encodes the 
cardiac troponin I (Figure 38).  The patient initially presented with aborted SCD, and no 
observable hypertrophy.  However, symptoms progressed to a point necessitating cardiac 
transplantation.  Here I use genetic engineering strategies to evaluate the structural and 
functional consequences of this novel mutation in TNNI3, which is otherwise not expressed in 
hiPSC-CMs, providing the first hiPSC-CM RCM model and demonstrating feasibility for 
evaluating the physiological consequences of the RCM mutation in hiPSC-CMS.  
3.3 Materials and methods 
Primary myocyte isolation 
Ventricular myocytes from mouse and rabbit were isolated by a modified 
collagenase/protease method as previously described [38].  All the experiments conducted in 
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Tyrode’s solution containing (in mM): CaCl2, NaCl 134, KCl 5.4, MgCl2 1, glucose 10, and 
HEPES 10, pH adjusted to 7.4 with NaOH.  Final concentration of Ca was 2 mM. 
Human iPSC derivation and culture 
Human induced pluripotent stem cells (hiPSCs) were generated, as described above. 
Briefly, HCM line SCVI6-CM (HCM; MYH7 Arg663His) and control SCVI13-CM (Family 
member; WT unaffected) were derived from skin fibroblast by lentivirus with the 4 Yamanaka 
factors  at Stanford University.  DCM line LVIP4 was generated from left ventricular cardiac 
fibroblast by episomal based reprogramming.  All protocols were approved by the respective 
institutions Institutional Review Board.  For all reprogramming individual colonies with typical 
hESC morphology were picked at day 17 to 30 and clonally expanded.  All hiPSCs exhibit 
normally karyotype. hiPSC lines were routinely maintained on Matrigel, growth factor-reduced 
1:200 (Corning) or on Synthemax II-SC coated plates in mTeSR1 medium (Stemcell 
Technologies) or E8 medium (Stanford University).  Cells were passaged every 4 days using 
0.5 mM EDTA (Life Technologies) in D-PBS without CaCl2 or MgCl2 (Life Technologies). 2 µM 
thiazovivin (Selleck Chemicals) or 10 µM Rho kinase inhibitor Y-27632 (CalBiochem) was 
added for the first 24hrs after passaging.  Cells were maintained at 37ºC, with 5% CO2 and 5% 
O2.. 
Generation of Adenoviral Vectors 
Recombinant adenovirus vectors were engineered as previously described [45] by 
transfecting shuttle plasmids containing cardiac troponin I (cTnI) cDNAs and Ad-5-derived 
plasmid into HEK 293 cells.  Each shuttle plasmid had a CMV promoter, along with WT or 
mutant cTnI and a bicistronic mCherry cassette.  Each virus was titered, plaque-purified and 
stored at – 80 C until use.  
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Measurement of intracellular Ca 
Myocytes were loaded with Fura-2 acetoxymethyl ester, Fura-2 AM (Molecular Probes 
Inc, Eugene, OR) as described previously [38].  Briefly, myocytes were incubated with 2 μM 
Fura 2 AM for 8 minutes at room temperature to load the indicator in the cytosol.  Myocytes 
were washed twice for 10 minutes with Tyrode’s solution containing 250 μM probenecid to retain 
the indicator in the cytosol.  A minimum of 30 min were allowed for de-esterification before 
imaging the cells. Fura 2-AM loaded myocyte Ca transients recorded during 0.5 Hz field 
stimulation in 2 mM Ca Tyrode’s solution for 20 second at room temperature.  Then stimulation 
was switched off followed by application of caffeine 10 mM for 5 second to estimate SR Ca 
content.  A subset of cells was exposed to 0Ca0Na Tyrode’s solution for 10 seconds then 
caffeine 10 mM applied for 30 second to estimate non-NCX Ca extrusion.  For each cell and 
each experimental condition, tau (τ), amplitude and baseline values were averaged from 3 
consecutive Ca transients.  Ca transients were recorded and analyzed using commercially 
available data analysis software (IonOptix, IonWizardTM Milton, MA).  All experiments were 
conducted at room temperature.  Briefly, myocytes were incubated with 2 μM Fura 2 AM for 8 
minutes at room temperature to load the indicator in the cytosol.  Myocytes were washed twice 
for 10 minutes with Tyrode’s solution containing 250 μM probenecid to retain the indicator in the 
cytosol.  A minimum of 30 min were allowed for de-esterification before imaging the cells. Fura 
2-AM loaded myocyte Ca transients recorded during 0.5 Hz field stimulation in 2 mM Ca 
Tyrode’s solution for 20 second at room temperature.  Then stimulation was switched off 
followed by application of caffeine 10 mM for 5 second to estimate SR Ca content.  A subset of 
cells was exposed to 0Ca0Na Tyrode’s solution for 10 second then caffeine 10 mM applied for 
30 second to estimate non-NCX Ca extrusion.  For each cell and each experimental condition, 
tau (τ), amplitude and baseline values were averaged from 3 consecutive Ca transients. Ca 
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transients were recorded and analyzed using commercially available data analysis software 
(IonOptix, IonWizardTM Milton, MA).  All experiments were conducted at room temperature. 
Video based edge detection 
Video edge detection was used to assess cellular contraction (i.e., cell shortening) of 
contracting CMs.  Briefly; CMs were visualized using Nikon Ellipse T5100 coupled to IonOptix 
video microscopy system (IonOptix).  Spontaneous or field stimulated contraction traces were 
recorded in 2 mM Ca Tyrode solution.  For each cell and each experimental condition typical 
contraction parameters including percent cell shortening (i.e., percent of resting cell length) and 
contractile kinetics (i.e., time to peak 90% and time to baseline 90%) values were averaged. 
Contraction traces were recorded and analyzed using commercially available data analysis 
software (IonOptix, IonWizardTM Milton, MA).  Only isolated hiPSC-CMs with aspect ratio 
greater than or equal to 4 were used, non-shortening cells were excluded from analysis. 
Hysteresis loop analysis 
Hysteresis loops were constructed as described before [46].  Briefly, representative 
HCM and control, Ca transient and cell shortening trace were selected by highlighting in 
IonWizardTM software (IonOptix, Milton, MA).  Both Ca transient amplitude data (Fratio) and cell 
shortening trace data (um) were exported and pasted into Microsoft Excel.  In Microsoft Excel 
duplicated were removed, this function is found under the data tab, by highlighting both time and 
length or time and ratio then selecting only the time variable.  Such that for each time point there 
was a corresponding cell length measurement and Ca transient amplitude ratio.  Cell shortening 
values were multiplied by -1 to convert all values to positive numbers and were plot on the Y-
axis as a function of Ca transient amplitude values on the X-axis.  
Potential hysteresis loop characteristics: 
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 Positive inotrope, increased area and upward shift of the hysteresis loop 
 Negative inotrope, decreased area and downward shift of the hysteresis loop 
 Myofilament Ca sensitizer, upward leftward shift of the hysteresis loop 
 Myofilament Ca desensitizer, downward rightward shift of the hysteresis loop 
 Larger loop area, indicated higher contractile function 
Western blot analysis 
Western blot analysis was carried out as described [39]. Briefly, hiPSC-CMs were 
seeded on mattress or non-mattress (1:60 Matrigel) for 5 days. hiPSC-CMs were lysed with 
RIPA buffer supplemented with protease inhibitor and phosphatase inhibitor cocktail (Sigma).  
To remove excess Matrigel from mattress lysates, all lysates were centrifuged at 16,000 rpm for 
15 minutes at 4°C. Protein was quantified using Bio-Rad DC Protein Assay.  five µg of protein 
lysates were resolved on 12 % mini-Protean TGX gels (Bio-rad) and transferred onto 
nitrocellulose membranes for immunoblotting.  Membranes were incubated with primary 
antibodies α-tubulin (rabbit monoclonal, Abcam), ssTnI (rabbit polyclonal, Sigma), cTnI (rabbit 
polyclonal, Abcam) overnight at 4°C. LI-COR. LI-COR secondary antibody were used and 
detected by Odyssey CLX (LI-COR) per manufacturer’s protocol.  Protein band intensities were 
quantified and normalized to alpha-tubulin band intensities using Li-COR Image Studio 
software. 
Immunohistochemistry 
Immunostaining of CMs was carried out as before [13].  Briefly, CMs were fixed in 2% 
paraformaldehyde for 5 minutes at room temperature, permeabilized with 0.2% Triton X-100 
(Sigma) for 10 minutes at 4 C.  Samples were blocked with 1% BSA in PBS solution and 
incubated for 1 hour at room temperature.  Primary antibody, a-actinin (mouse monoclonal, 
Sigma), was added in 0.1% Triton X-100 1% BSA in PBS solution and incubated overnight at 4 
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C. Samples were washed with 0.2% Tween 20 in PBS, secondary antibodies specific to the 
primary IgG isotype were diluted (1:1000) in the same solution as the primary antibodies and 
incubated at room temperature for 1 hour.  Samples were washed with 0.2% Tween 20 in PBS 
twice and mounted. Slides were examined with Olympus IX81 microscope coupled to Slidebook 
software.  For morphometric analysis images were imported into Image J and analyzed using 
standard plugins. 
Electron micrograph 
A ten cm dish of day 30 control hiPSC-CMs and DCM hiPSC-CMs were washed to 
remove debris, then immediately fixed in 2.5% gluteradehyde in 0.1 M sodium cacodylate buffer 
for 1 hour at room temperature.  Next samples were exposed to a secondary fixation (osmium 
tetroxide) and dehydration and resin infiltration steps followed by sectioning and embedding 
samples. 
Sanger sequencing 
Cardiac fibroblasts were isolated for RCM patient explanted heart.  Briefly, left 
ventricular tissue was processed by mincing tissue with scalpel.  Minced tissue were plated in 
10 cm tissues culture dish and incubated at 37 C in fibroblast growth medium 2 C-23020 until 
fibroblast are observed proliferating from tissue.  Cardiac fibroblast were expanded and 
processed for sanger sequencing.  Genomic DNA was isolated and separated on an agarose 
gel, the bands were then excised processed and sequenced. 
Statistical analysis 
Data are mean ± SD unless indicate otherwise.  Statistical differences between two 
groups were tested with two-tailed Student’s t test.  Statistical differences among more than two 
groups were assessed using one-way ANOVA followed by tukey or bonferroni correction. 
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Results were considered statistically significant if the p-value was less than 0.05.  Statistical 
analysis was performed using Graphpad Prism 6. 
3.4 Results 
HCM MYH7 A663H hiPSC-CMs exhibit altered twitch Ca handling properties 
The structural results of the HCM MYH7 A663H mutation in hiPSC-CMs have been 
previously described including cellular hypertrophy and increased multinucleation [13].  Feng 
and colleagues also purpose a potential HCM MYH7 A663H mechanism of increased Ca 
sensitivity (i.e., affinity) (Figure 29).  I hypothesized that HCM MYH7 A663H hiPSC-CMs exhibit 
distinct differences in functional phenotypes relative to control hiPSC-CMs.  Here I set out to 
expand on the previous reports for the HCM MYH7 A663H mutation and implement the Matrigel 
mattress method to perform a detailed assessment of contractile properties and Ca handling.  I 
hypothesize that HCM MYH7 A663H hiPSC-CMs will display altered twitch Ca transients 
including decreased Ca decay and kinetics (Figure 30) resulting in abnormal contractile 
properties at the single hiPSC-CM level.  I first evaluated intracellular twitch Ca handling of 
HCM MYH7 A663H hiPSC-CMs and mutation negative family member controls hiPSC-CMs 
(Stanford University).  Although HCM MYH7 A663H hiPSC-CMs display comparable Ca 
transient amplitude (Figure 30 A and B) as control, I discovered HCM MYH7 A663H hiPSC-CMs 
exhibit slower Ca decay rates (Figure 30 A and B) along with prolonged Ca handling kinetics 
(Figure 30 A and B).  These results suggest the HCM MYH7 A663H mutation may exert an 
effect by modulating myofilament Ca sensitivity and hence Ca removal from the cytoplasm. 
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Figure 29. Proposed HCM MYH7 mechanism and nodes of intervention. Mutation in the thick 
filament protein β-myosin heavy chain may increase Ca affinity which in turn increases 
intracellular Ca concentration. This pathological increase in Ca may have consequences such 
as: increased calcineurin NFAT signaling, ultimately initiating a hypertrophic response. And Ca 
handling defects and provides an arrhythmia substrate which may be exacerbated by enhanced 
β- Adrenergic stimulation. Fen et al. propose therapeutic options including L-type Ca channel 
blockers, which may reduce the increased intracellular Ca concentration. Calcineurin NFAT 
signaling inhibitors, to reduce the pathological hypertrophy and  β blockers to reduce arrhythmic 
occurrence and attenuate  hypertrophy. (Feng L. et al., Cell Stem Cell 2013; 12, 101-103). 
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Figure 30. HCM (MYH7 R663H mutation) hiPSC-CMs Ca handling. A, Representative twitch 
calcium transient from HCM (Red) and Control (Black) hiPSC-CM. B, Data are mean ± SEM (n 
= 6 – 35 cells per group). *P<0.05 vs control hiPSC-CMs. Data show significate Ca handling 
abnormalities including decreased decay rate and prolonged kinetics. 
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Contractile dysfunction of HCM MYH7 A663H hiPSC-CMs 
To determine if the altered twitch Ca handling properties translate to dysfunction in 
cellular contractions, I implement our novel culture method [24], to elucidate the contractile 
consequences of the HCM MYH7 A663H mutation.  I found that HCM MYH7 A663H hiPSC-
CMs display significantly increased cellular contraction (Figure 31 and table 5) relative to control 
hiPSC-CMs.  In addition I discovered HCM MYH7 A663H hiPSC-CMs display significantly 
prolonged contraction and relaxation kinetics (Figure 31 C and table 5) consistent with 
increased Ca affinity.  Next, I use the Matrigel mattress method to simultaneously evaluate 
contractile properties and Ca handling properties to get a representation of the HCM MYH7 
A663H hiPSC-CM Ca sensitivity.  This is done by hysteresis loop analysis (Figure 32) by 
plotting the cell shortening amplitude as a function of the peak Ca transient amplitude to 
elucidate possible alterations in the calcium-contraction relationship.  When compared to control 
hiPSC-CM hysteresis loop I discovered that HCM MYH7 A663H hiPSC-CMs display increased 
contraction at lower Ca concentrations, as indicated by the upward shift in the hysteresis loop 
(Figure 33),  suggesting that the HCM MYH7 A663H mutation result in increased myofilament 
Ca sensitively. 
Since MYH7 is associated with increased risk of arrhythmia I evaluated if the HCM 
MYH7 A663H mutation created a proarrhythmic substrate in vitro and if such effects could be 
assessed by differences in the HCM MYH7 A663H hiPSC-CM contractile morphology (e.g., 
DAD and EAD).  I found HCM MYH7 A663H hiPSC-CM display significantly increased number 
of cells with irregular contractile transients (Figure 34).  These data provide the first detailed 
assessment of twitch Ca handling and contractile properties of HCM MYH7 A663H hiPSC-CM. 
  
93 
 
 
Figure 31. HCM R663H contractile assessment. A, Representative contraction trace of control 
(Black) and B, HCM (Red) MYH7 R663H hiPSC-CM. C, Data are mean ± SEM (n = 5 - 29 cells 
per group). Data show HCM R663H hiPSC-CMs have significantly increased cell shortening % 
and prolonged kinetics relative to control hiPSC-CMs. *P<0.05 vs control hiPSC-CMs.  
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Figure 32.  Hysteresis loop parameters. Graph depicts typical calcium – contraction hysteresis 
loop. The counterclockwise loop represents contraction (I) and relaxation (II) that ultimately 
converge, with the same trajectory, to baseline.  
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Figure 33.  HCM R663H hysteresis loop. Representative HCM R663H hysteresis loop, HCM 
(red) and control (black). Calcium – contraction loop demonstrating hiPSC-CM carrying the 
HCM R663H MYH7 mutation have increased contractile performance and increased 
myofilament calcium sensitivity indicated by the upward shift and increased contraction at lower 
Ca concentrations respectively. 
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Figure 34. Contractile arrhythmia assessment. A, Representative contraction trace of control 
and HCM R663H hiPSC-CM, red arrows indicate irregular contraction morphology. B, Data are 
mean (n = 9 –  40 cells per group). Fisher exact test P < 0.0010. 
  
97 
 
 
Table 5. HCM R663H contractile assessment. Data are mean ± SEM. 
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DCM hiPSC-CMs exhibit myofilament disarray 
For these experiments patient specific hiPSC-CMs were generated from left ventricular 
cardiac fibroblasts obtained for explanted heart samples and reprogrammed by the plasmid-
based reprogramming as described above.  To determine if the DCM hiPSC-CMs display 
ultrastructure abnormalities I performed electron microscopy and immunofluorescence staining 
of the sarcomere component α-actin.  I found that DCM hiPSC-CMs exhibit structural 
differences at the cellular level including myofilament disarray and mitochondrial defects (Figure 
35).  
DCM hiPSC-CMs display Ca handling dysfunction 
To determine if there is a Ca handling defect I evaluated Ca handling properties in DCM 
and control hiPSC-CMs.  I found that DCM hiPSC-CMs have normal diastolic Ca, Ca transient 
amplitude, and Ca decay (i.e., SERCA activity) (Figure 36). However detailed analysis of Ca 
kinetics and SR contribution by caffeine application revealed that DCM hiPSC-CMs display 
significantly prolonged Ca handling kinetics (i.e., time to peak) and significantly increased SR 
content (Figure 36 B and C).  These data support the utility of hiPSC-CMs for disease modeling 
and for elucidating the consequences of a novel DCM hiPSC-CM model. 
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Figure 35. DCM hiPSC-CM ultrastructure. Transmission electron microscopy images and 
immunofluorescence staining of myofilament organization for cardiac marker α-actinin (green). 
A and B, control hiPSC-CM. C and D, DCM hiPSC-CM. White arrows indicate sarcomere 
disarray. Scale bar 10 µM.  Panel B and D Courtesy of Dr. Young Wook Chun. 
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Figure 36. Calcium handling of DCM hiPSC-CMs. A, Representative Ca twitch transients, 0.2 
Hz. B, Representative caffeine transients [10 mM]. C, Data are mean ± SEM (n = 5 - 29 cells 
per group). Control (Black) and DCM (Blue). Data show altered Ca handling properties in DCM 
hiPSC-CMs including prolonged kinetics and increased SR Ca content. *P<0.05 vs control 
hiPSC-CMs. 
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Assessment of RCM TNNI3 R204C mutation 
Here I set out to determine the cellular consequence of the heterozygous de novo 
arginine-to-cysteine mutation at position 204 (R204C) of the TNNI3 gene which encodes cardiac 
troponin I.  Since TNNI3 is a component of the troponin complex that senses intracellular calcium 
Ca concentration to regulate actomyosin activity, I hypothesized that the TNNI3 R204C mutation 
causes specific changes in the CM physiology, and that these perturbations will be manifested in 
the hiPSC-CMs through distinct differences in a wide range of cellular phenotypes, including 
morphology, Ca handling and contractility.  As an independent confirmation of the missense 
mutation I performed nucleotide sequence analysis to demonstrate the TNNI3 R204C mutation 
(Figure 37 B) present in the patient tissue.  Subsequent evaluation of the probands parents 
revealed no known mutation (Figure 37 A).  In addition polyphen analysis suggests that the 
TNNI3 R204C mutation is damaging (Figure 37 D) and located in a highly conserved region of 
the protein (Figure 37 C).  Here, we employ recombinant adenovirus expressing WT or mutant 
(R204C) TNNI3 to determine the pathogenicity of the TNNI3 R204C mutation by elucidating the 
structural and functional consequences of the TNNI3 R204C mutation in a human CM 
background in hopes of identifying novel mechanistic insight.  
Cardiac Troponin I expression in hiPSC-CMs 
As previously shown [14] hiPSC-CMs cultured under standard conditions do not express 
cardiac troponin I, rather they primarily express the fetal slow skeletal troponin I isoform (Figure 
38).  As a first step to assess the function of mutant cardiac troponin I in hiPSC-CMs I establish 
the troponin I molecular signature of the hiPSC-CMs used in this study.  Consistent with other 
reports, the hiPSC-CM used in this study primarily express the fetal slow skeletal troponin I 
protein relative to human control as assessed by Western blot analysis (Figure 39) and 
immunofluorescence staining for cardiac troponin I (Figure 39 C).  Therefore to evaluate the 
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consequences of TNNI3 R204C mutation in hiPSC-CMs I engineered two adenovirus 
constructs, one to overexpress WT and one to overexpress mutant TNNI3 (Figure 40).  As a 
first step in this study it is critical to demonstrate the recombinant proteins are expressed and 
incorporated in hiPSC-CMs.  
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Figure 37. Validation of RCM mutation. A, Pedigree of RCM patient family indicating de novo 
mutation (Open square (male) and circle (female)). Filled in circle represents individual carrying 
de novo mutation R204C in TNNI3 which encodes the protein cardiac troponin I. B, The R204C 
point mutation was confirmed in the RCM patient by PCR and sequencing analysis. C, 
Organization of human cardiac troponin I.  The red star indicated the location of the de novo 
R204C mutation. D, Genetic analysis indicating the TNNI3  R204C mutation is likely damaging. 
(Mogensen J. et al., The Journal of Clinical Investigation  2003; 111(2): 209–216).  
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Figure 38. Cardiac troponin I isoform switch in hiPSC-CMs. A, Representation of human 
Troponin I isoform switch. B, hiPSC-CM relative troponin isoform expression. C, Troponin I 
isoform expression of Adenovirus cTnI infected hiPSC-CMs demonstrating increased cTnI 
expression and D, reduced fetal isoform ssTnI expression. (Bedada F. et al., Stem Cell Reports 
2014; 3(4): 594–605). 
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Figure 39.  Troponin I isoform confirmation hiPSC-CM. A, Western blot for indicated troponin 
protein. Patient left ventricular tissues (left panel) and hiPSC-CMs (right panel). cTnI and ssTnI 
(24 kDa). B, Relative troponin protein expression ssTnI (left panel), cTnI (right panel). C, 
Immunofluorescence staining of hiPSC-CMs for DAPI (Blue), α-actinin (Green) and cardiac 
troponin I, cTnI (red). Panel C courtesy of Dr. Young Wook Chun.  Data show cardiac troponin I 
is poorly expressed in the hiPSC-CMs used in this study. However, cardiac troponin I is robustly 
expressed in RCM patient left ventricular tissue. 
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Figure 40.  TNNI3 Adenovirus constructs.  A, wild type (WT) TNNI3.  B, Mutant R204C TNNI3. 
Each construct is engineered with a C-terminal flag tag and a bicistronic mCherry cassette.  
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Expression and sarcomeric incorporation of WT and mutant TNNI3 in hiPSC-CMs  
Adenovirus was added directly to CM culture media at a multiplicity of infection (MOI) of 
200. Robust expression of mCherry was detected as early as 24 hours post transduction with 
greater than 90% transduction efficiency (Figure 41 A). For comparison we used freshly isolated 
adult rabbit-CM which displayed greater than 90% transduction efficiency (Figure 41 B).  Next 
adenovirus transduced WT and mutant hiPSC-CMs were processed for immunofluorescence 
and Western blot analysis at ~36 hours post transduction (Figure 42).  Each recombinant 
adenovirus construct was engineered with C-terminal flag tag to distinguish recombinant from 
any endogenous cardiac troponin I.  To assess sarcomeric incorporation transduced hiPSC-
CMs were immunostained with anti-flag antibody.  As shown in (Figure 42 A) both WT and 
mutant recombinant troponin I successfully localize and incorporate into the myofilament in 
hiPSC-CMs.  Western blot analysis confirmed adenoviral troponin I protein expression. As 
shown in (Figure 42 B) transduced WT and R204C mutant hiPSC-CMs exposed to anti-flag 
antibody display a detectable band at ~24 kDa.  This band corresponds to the appropriate 
molecular weight of cardiac troponin I.  These data are proof of feasibility for structural and 
functional analysis of the RCM TNNI3 R204C mutation in hiPSC-CMs. 
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Figure 41.  Adenoviral transfection efficiency.  A, Bright field and immunofluorescence images 
of hiPSC-CMs (day 30), 72 hours post infection with WT or mutant troponin adenovirus.  Scale 
bar, 100 µm.  B, Immunofluorescence images of adult rabbit-CMs, 24 hours post infection with 
WT or mutant troponin adenovirus.  20X mCherry (red) MOI 200. Scale bar, 50 µm. 
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Figure 42.  Ad-TNNI3 expression and incorporation.  A, Immunofluorescence images of 
adenoviral infected hiPSC-CMs (day 30) 72 hours-post infection.  Anti-flag (green) 63X. B, 
Western blot of protein from adenoviral infected hiPSC-CMs for anti-Flag.  Scale bar, 20 µm. 
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3.5 Discussion 
The heritable causes of sarcomeric cardiomyopathies have been elucidated.  However, 
the mechanisms for these diseases are less clear.  Previous studies of hypertrophic 
cardiomyopathy [13] and dilated cardiomyopathy [12] provide evidence supporting the use of 
hiPSC-CMs to model sarcomeric cardiomyopathies.  However, these studies only peripherally 
evaluated Ca handling and contractility at the single hiPSC-CM level and detailed analysis have 
not been reported.  Here, I demonstrate assessment of Ca handling and mechanical contractile 
properties of human cardiomyopathy.  Major findings are HCM MYH7 A663H hiPSC-CM display 
slower Ca decay and prolonged Ca kinetics compared to control hiPSC-CMs (Figure 30).  By 
implementing the Matrigel mattress platform I uncover HCM MYH7 A663H hiPSC-CMs exhibit 
severe contractile abnormalities at the single cell level including significantly increased 
contractility, diastolic dysfunction and significantly increased contractile arrhythmic events 
(Figure 31), consistent with clinical hallmarks of HCM.  Further using hysteresis loop analysis I 
provided evidence supporting a myofilament Ca sensitivity mechanism (Figure 33).  These data 
suggest the HCM MYH7 A663H phenotype may be caused, in part, by decreased SERCA 
activity, as shown by decrease twitch Ca decay, and prolonged Ca kinetics.  However, the Ca 
handling experiments assume comparable Ca buffering and flux properties, which may not be 
the case.  Additional experiments will need to be performed to determine if the Ca buffing is 
altered in these cells including the Ca dissociation constant.  As such, we are currently 
performing cytoplasmic Ca buffering and flux experiments to address the underlining 
mechanisms of increased myofilament Ca sensitivity and altered Ca removal regulation. 
The DCM experiments reveal abnormal ultrastructure features, altered mitochondria and 
irregular Ca handling properties (Figure 35 and 36).  These studies together with the HCM 
MYH7 A663H analysis create a foundation for detailed pathophysiological studies using hiPSC-
CMs.  Further experiments using DCM hiPSC-CMs will need to be performed to quantify the 
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mitochondrial defects and determi ne if there is a direct association between the mitochondrial 
defects and Ca handling dysfunction.  Finally it will be interesting to see if the DCM Ca handling 
abnormalities result in contractile dysfunction in DCM hiPSC-CMs plated on the Matrigel 
mattress platform. 
The RCM studies used a recombinant adenovirus construct (Figure 40) to demonstrate 
feasibility for evaluating the functional consequences of the novel TNNI3 R204C mutation.  I 
show both WT and mutant construct successfully express troponin I (Figure 42 B) that is 
incorporated to the sarcomere (Figure 42 A) in hiPSC-CMs.  A caveat for such experiments is 
that typical recombinant overexpression studies create a non-physiological environment.  
However, for the cardiac troponins excess troponin is rapidly degraded reducing the possibility 
of a non-physiologic sarcomere in vitro.  From a translational perspective, these data provide a 
foundation for future “personalized platforms” to evaluate individuals at risk of developing heart 
failure, fatal arrhythmias, and to develop future targeted therapies. 
Limitations 
These results are specific to the in vitro consequences of the particular mutation for example 
MYH7 A663H or TNNI3 R204C and do sarcomeric cardiomyopathy in general.  While I present 
significant changes in patient specific DCM hiPSC-CMs I do not present a causal mutation, this 
limits the utility and translatability of this characterization.  However, using next generation 
sequencing and CRISPR/Cas9 technology studies we are actively working to determine the 
casual mutation in these cells. 
Furthermore, the contribution of inositol triphosphate (IP3) sensitive intracellular Ca 
stores were not assess in control or diseases hiPSC-CMs.  hESC-CMs display prominent 
inositol triphosphate (IP3) sensitive intracellular Ca stores.  These Ca stores are not thought to 
play a role in healthy adult ventricular CMs physiology however they can be upregulated in 
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diseased CMs [47].  Future studies will determine if IP3 Ca stores are present and the effects 
healthy and diseased hiPSC-CMs function.   
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Chapter 4 
hiPSC-CM DRUG SCREENING 
4.1 Chapter Abstract 
Drug screening and cardiotoxicity efforts are lacking greatly limiting discovery of novel 
HF pharmacotherapies.  Here, I set out to establish the utility of hiPSC-CMs and the mattress 
platform for evaluation and identification of novel HF compounds, by demonstration of their 
pharmacological response to known compounds.  Although hiPSC-CMs exhibit a modest 
inotropic response to adrenergic stimulation (Isoproterenol and Epinephrine ~ 4% and ~ 6% 
above vehicle, respectively) they do display a robust chronotropic response (Isoproterenol 75 % 
increase above vehicle). I further demonstrate hiPSC-CMs display a robust response to 
compounds that modulate nodes of EC coupling such as extracellular Ca, Verapamil and 
myofilament Ca sensitizers (i.e., EMD57033 and Levosimendan) , which has previously not 
been demonstrated in single hiPSC-CM.  And with the implementation of the mattress platform I 
demonstrate contractile efficacy for a novel inotrope, EHF1.  These experiments show hiPSC-
CMs are a valuable tool for assessment of contractile function of known and novel 
pharmacological agents, in intact human CMs. 
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4.2 Introduction 
Cardiac drug screening and toxicology efforts are hindered largely due to a lack of 
available human CMs, or a reliable surrogate, that may be used to identify novel targets and 
compounds without hazardous liabilities.  This has led to high drug attrition rates, costly late 
withdrawal of toxic compounds, and even premature termination of safe compounds.  HiPSC-
CMs represent a strategy to address this need by enabling standardized human CMs for drug 
screening purposes and toxicology assessment. 
To date researchers primarily use animal models to evaluate drug efficacy and safety.  
While useful, these models do not recapitulate certain aspect of human biology, as animals 
represent different genetic backgrounds, protein expression and physiological contribution of 
such proteins.  The lack of an adequate system to asses cardiac drug response has led to poor 
heart failure therapeutic candidates and high and increasing prevalence of HF.  
For these reasons, to obtain improved and safer drugs, the Food and Drug 
Administration has implemented mandatory cardiac safety requirements (i.e., ICH S7A and 
S7B) [48] for all compounds.  This comes after cases of death or adverse drug reactions, for 
both drugs with cardiac and non-cardiac indications.  The main assay for evaluating 
cardiotoxicity is the hERG channel assays, which identifies compounds that prolong the QT 
interval in vitro.  These compounds could provide a proarrythmic substrate for early after-
depolarization (EAD) or delayed after-depolarization (DAD) and ultimately result in Torades de 
Pointes (TdP) a potentially fatal arrhythmic event.  However hERG channel assays are 
notorious for false positive (e.g., alfuzosin) and false negative (e.g., verapamil) results which 
limits their utility for identifying safe drugs.  As such a wide appreciation has been developed for 
evaluation of compound effects on multiple channels and accessory proteins, simultaneously; 
which may better represent human biology.  Moreover hiPSC-CMs have gained significant use 
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in this effort. However, much still needs to be learned particularly at the cellular level.  The lack 
of simple single cell contractility methods has hindered drug screening and toxicity efforts.  
Currently we do not have a clear understanding of how hiPSC-CMs respond to pharmacological 
stimuli [49, 50] and if these cells are useful for identifying compounds and validating targets. 
Here we take advantage of hiPSC technology, as well as our novel contractile method to 
elucidate the effects of pharmacological compounds on modulating hiPSC-CM EC coupling to 
better understand the utility of these cells.  Next, we determine if hiPSC-CMs are capable of 
identifying novel inotropes with efficacy in human CMs. 
4.3 Materials and methods 
Primary myocyte isolation 
Ventricular myocytes from mouse and rabbit were isolated by a modified 
collagenase/protease method as previously described [38].  All the experiments conducted in 
Tyrode’s solution containing (in mM): CaCl2, NaCl 134, KCl 5.4, MgCl2 1, glucose 10, and 
HEPES 10, pH adjusted to 7.4 with NaOH.  Final concentration of Ca was 2 mM. 
Compounds and pharmacological assay  
All compounds were re-suspended based on manufactures recommendations.  Briefly, 
EMD57033 (Sigma) was prepared in DMSO and Verapamil (Sigma) was prepared in distilled 
water.  
Before experiments, individual hiPSC-CMs were selected based on normal contraction 
and morphology.  HiPSC-CMs with no obvious baseline, irregular contractions or aspect ratio 
less than 4 were not selected for analysis.  The position of suitable hiPSC-CMs was recorded. 
Each experiment typically measured pharmacological response for 5 to 20 hiPSC-CMs taken 
from independent cardiac differentiations.  HiPSC-CMs were perfused with Tyrode’s solution 
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with vehicle and allowed to equilibrate for approximately 5 minutes before experiments.  The 
positive inotrope EMD57033 was used with external Ca concentration 1 mM Tyrode around the 
EC50. HiPSC-CMs were exposed to increasing concentration of compound for 250 seconds or 
until steady state was reached [51]. 
Hysteresis loop analysis 
Hysteresis loops were constructed as described before [46].  Briefly, select 
representative Ca transient and cell shortening trace, for each compound by highlighting 
recording in IonWizardTM software (IonOptix, Milton, MA).  Both Ca transient amplitude data 
(Fratio) and cell shortening trace data (um) were exported and pasted into Microsoft Excel.  In 
Microsoft Excel duplicates were removed, this function is located under the data tab.  Both time 
and length or time and ratio were highlighted and duplicates removed by selecting only the time 
variable.  Such that for each time point there was a corresponding cell length measurement and 
Ca transient amplitude ratio.  Next, all Ca transient amplitude values were normalized to the 
baseline Ca transient ratio.  And all cell length measurements were normalized to the resting 
cell length.  Transformed cell length data was multiplied by -1 to make all values positive.  
Normalized cell shortening values were plotted on Y-axis as a function of normalized Ca 
transient amplitude values on the X-axis.  
Potential hysteresis loop characteristics: 
 Positive inotrope, increased area and upward shift of the hysteresis loop 
 Negative inotrope, decreased area and downward shift of the hysteresis loop 
 Myofilament Ca sensitizer, upward leftward shift of the hysteresis loop 
 Myofilament Ca desensitizer, downward rightward shift of the hysteresis loop 
 Larger loop area, indicated higher contractile function 
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Immunohistochemistry 
Immunostaining of hiPSC-CMs was carried out as before [52].  Briefly, day 30 hiPSC-
CMs were fixed in 2% paraformaldehyde for 5 minutes at room temperature, permeabilized with 
0.2% Triton X-100 (Sigma) for 10 minutes at 4 C.  Samples were blocked with 1% BSA in PBS 
solution and incubated for 1 hour at room temperature.  Primary antibody, phospho-PKA 
(Sigma), was added in 0.1% Triton X-100 1% BSA in PBS solution and incubated overnight at 4 
C.  Samples were washed with 0.2% Tween 20 in PBS, secondary antibodies specific to the 
primary IgG isotype were diluted (1:1000) in the same solution as the primary antibodies and 
incubated at room temperature for 1 hour.  Samples were washed with 0.2% Tween 20 in PBS 
twice and mounted.  Slides were examined with Olympus IX81 microscope coupled to 
Slidebook software. 
Measurement of intracellular Ca 
Myocytes were loaded with Fura-2 acetoxymethyl ester, Fura-2 AM (Molecular Probes 
Inc, Eugene, OR) as described previously [38].  Briefly, myocytes were incubated with 2 μM 
Fura 2 AM for 8 minutes at room temperature to load the indicator in the cytosol.  Myocytes 
were washed twice for 10 minutes with Tyrode’s solution containing 250 μM probenecid to retain 
the indicator in the cytosol.  A minimum of 30 minutes was allowed for de-esterification before 
imaging the cells. Fura 2-AM loaded myocyte Ca transients recorded during 0.5 Hz field 
stimulation in 2 mM Ca Tyrode’s solution for 20 second at room temperature.  Then stimulation 
was switched off followed by application of caffeine 10 mM for 5 second to estimate SR Ca 
content.  A subset of cells were exposed to 0Ca0Na Tyrode’s solution for 10 second then 
caffeine 10 mM applied for 30 second to estimate non-NCX Ca extrusion.  For each cell and 
each experimental condition, tau (τ), amplitude and baseline values were averaged from 3 
consecutive Ca transients. Ca transients were recorded and analyzed using commercially 
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available data analysis software (IonOptix, IonWizardTM Milton, MA).  All experiments were 
conducted at room temperature. 
Video based edge detection 
Video edge detection was used to assess cellular contraction (i.e., cell shortening) of 
contracting CMs.  Briefly; CMs were visualized using Nikon Ellipse T5100 coupled to IonOptix 
video microscopy system (IonOptix).  Spontaneous or field stimulated contraction traces were 
recorded in 2 mM Ca Tyrode solution.  For each cell and each experimental condition typical 
contraction parameters including percent cell shortening (i.e., percent of resting cell length) and 
contractile kinetics (i.e., time to peak 90% and time to baseline 90%) values were averaged. 
Contraction traces were recorded and analyzed using commercially available data analysis 
software (IonOptix, IonWizardTM Milton, MA).  Only isolated hiPSC-CMs with aspect ratio 
greater than or equal to 4 were used, non-shortening cells were excluded from analysis. 
Statistical analysis 
Data are mean ± SD unless indicate otherwise.  Statistical differences between two 
groups were tested with two-tailed Student’s t test.  Statistical differences among more than two 
groups were assessed using one-way ANOVA followed by tukey or bonferroni correction. 
Results were considered statistically significant if the p-value was less than 0.05. Statistical 
analysis was performed using Graphpad Prism 6. 
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4.4 Results 
Pharmacological Response 
The application of hiPSC-CM contractile properties lies, for one example, in the ability to 
evaluate pharmacological response, for detailed analysis of hiPSC-CM EC coupling and 
practical applications including drug screening and preclinical cardiotoxity testing.  As such, the 
response of myofilaments to Ca is a key element of cardiac contractile function [18].  To 
elucidate if hiPSC-CMs respond to changes in myofilament sensitivity, hiPSC-CMs were plated 
on the Matrigel mattress platform and treated with the inotrope, EMD57033, a myofilament Ca 
sensitizer.  We found hiPSC-CMs respond to EMD57033 exhibiting a concentration-dependent 
increased in cellular contraction with ~ EC50 2.6 µM [22] (Figure 43 A lower panel and B) along 
with prolonged contractile kinetics (Figure 43 A lower panel) consistent with increase Ca affinity 
and negligible effect on intracellular Ca transient amplitude (Figure 43 A upper panel and C).  
This represents the first time single hiPSC-CMs have been shown to respond to myofilament 
sensitization demonstrating the utility of the mattress for identifying novel myofilament Ca 
sensitizers. 
We next assessed modulation of trans-sarcolemmal Ca by evaluating changes in 
extracellular Ca and application of verapamil, an L-type Ca channel blocker. Increased external 
Ca resulted in a concentration-dependent increase in cellular contraction with ~ EC50 1.2 mM 
[22] (Figure 44 A lower panel and B) and intracellular Ca ~ EC50 1.4 mM (Figure 44 A upper 
panel and C).  The prototypical negative inotrope, verapamil, markedly decreased cellular 
contraction ~ EC50 0.3 µM (Figure 45 A lower panel and B) and intracellular Ca ~ EC50 1.5 µM 
(Figure 45 A upper panel and C). 
Multiple reports have demonstrated a positive chronotropic response of single hiPSC-
CMs to isoproterenol, a β-adrenergic receptor agonist (Figure 51). However, the inotropic 
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effects are less understood [24].  Therefore, we evaluated the effect of Isoproterenol on 
contraction and Ca amplitude in hiPSC-CMs (Figure 45).  While we observed a modest 
concentration dependent increase in contraction (~ 4% above vehicle, ~EC50 0.8 nM [51]) 
(Figure 46 A lower panel and B) there was no change in Ca transient amplitude (Figure 46 A 
upper panel and C) in accordance with previous hiPSC-CM reports of lack of positive inotropic 
Ca transient amplitude response [23] [24].  To asses if a robust inotropic response could be 
observed with a mixed β-adrenergic receptor agonist we treated hiPSC-CMs with Epinephrine 
(Figure 47) similar to Isoproterenol we found a modest concentration dependent contraction 
response to Epinephrine (~ 6% above vehicle, ~EC50 9.3 nM [51]) (Figure 47 A lower panel and 
B). While or Ca transient amplitude analysis revealed a concentration dependent decrease at 
high test concentrations (Figure 47 A upper panel and C).  Taken together these results indicate 
hiPSC-CMs display modest but concentration dependent inotropic response to β-adrenergic 
stimulation.  These data confirm responses by hiPSC-CMs to pharmacological stimuli, thus 
validating the Matrigel mattress as a platform for detailed assessment of contractile response to 
novel small molecules for drug screening. 
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Figure 43.  EMD57033 pharmacological response.  A, Representative calcium transients (upper 
panel) and contraction traces (lower panel) for hiPSC-CMs treated with EMD57033 
(myofilament Ca sensitizer).  B, Contraction (Hill slope = 1.1) and C, Calcium concentration-
response curves.  Data show a concentration dependent increase in cell shortening % with 
negligible effect on Ca transient amplitude in hiPSC-CMs. EC
50
, effective concentration 50 % of 
max response.  Veh (vehicle). (Feaster T. et al., Circulation Research 2015; doi: 
10.1161/CIRCRESAHA.115.307580).    
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Figure 44.  Extracellular calcium pharmacological response.  A, Representative calcium 
transients (upper panel) and contraction traces (lower panel) for hiPSC-CMs treated with 
increasing concentration of extracellular Ca.  B, Contraction and C, Calcium concentration-
response curves.  (Hill slope = 18.7 and 2.6 respectively).  Data show a concentration 
dependent increase in cell shortening % and Ca transient amplitude. EC
50
, effective 
concentration 50 % of max response. Veh (vehicle).  (Feaster T. et al., Circulation Research 
2015; doi: 10.1161/CIRCRESAHA.115.307580). 
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Figure 45.  Verapamil pharmacological response.  A, Representative calcium transients (upper 
panel) and contraction traces (lower panel) for hiPSC-CMs treated with Verampamil.  B, 
Contraction and C, Calcium concentration-response curves.  (Hill slope = -1.8 and -0.9 
respectively).  . Data show a concentration dependent decrease in cell shortening % and Ca 
transient amplitude in hiPSC-CMs.  EC
50
, effective concentration 50 % of max response. Veh 
(vehicle). (Feaster T. et al., Circulation Research 2015; doi: 
10.1161/CIRCRESAHA.115.307580). 
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Figure 46.  Isoproterenol pharmacological response.  A, Representative calcium transients 
(upper panel) and contraction traces (lower panel) for hiPSC-CMs treated with Isoproterenol.  B, 
Contraction (Hill slope = 8.2) and C, Calcium concentration-response curves. Isoproterenol is a 
β adrenergic agonist (Figure 11).  Data show moderate concentration dependent increase in cell 
shortening % and negligible effect on Ca transient amplitude in hiPSC-CMs. EC
50
, effective 
concentration 50 % of max response. Veh (vehicle).  
125 
Figure 47.  Epinephrine pharmacological response.  A, Representative calcium transients 
(upper panel) and contraction traces (lower panel) for hiPSC-CMs treated with Epinephrine.  B, 
Contraction (Hill slope = 11.3) and C, Calcium (Hill slope = -2.2) concentration-response curves. 
Epinephrine is a nonselective adrenergic agonist.  In adult CMs Epinephrine increases Ca 
transient amplitude and contractile response.  Data show moderate concentration dependent 
increase  in cell shortening % and a concentration dependent decreased in Ca transient 
amplitude, at high test concentrations, in hiPSC-CMs.  EC
50
, effective concentration 50 % of 
max response. Veh (vehicle).  
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Hysteresis loop and contractile efficiency  
To get a more detailed view of the interaction between intracellular Ca and contraction 
and obtain a measure of the myofilament responsiveness (i.e., Ca sensitive) we re-plotted the 
data obtained from our Ca handling analysis and contractility analysis [46] as hysteresis loops 
(Figure 48).  To obtain these loops the cell shortening amplitude was normalized and plotted as 
a function of the normalized Ca transient amplitude.  A diagram of such is depicted in (Figure 
32), a contraction-Ca loops, provide yet another dimension of the EC coupling analysis in CMs.  
The counter-clockwise loop, similar to the pressure-volume loop relationship, can provide insight 
into potential mechanisms including potential compound liabilities [46].  When plotted as 
hysteresis loops the contractile function of pharmacological interventions or disease states can 
be assessed by alteration in the loop shape and location.  For instance, increasing extracellular 
Ca (Figure 48 A) results in upward shift and increased loop area suggests improved contractile 
function.  While treatment with Verapamil, L-type Ca channel blocker (Figure 48 C) results in 
downward shift and smaller loop area which suggests reduced contractile function.  Treatment 
with the myofilament Ca sensitizer, EMD57033, results in increased loop area, and upward 
leftward shift suggest increased contractile function (Figure 48 B).  In addition the mechanism of 
EMD57033 (i.e, myofilament Ca sensitizer), can be seen by the increased cell shortening at any 
given Ca concentrations, that is more contraction for less Ca (Figure 48 B).  Treatment with the 
β-adrenergic receptor agonist Isoproterenol results in an upward shift and an increased loop 
area suggesting enhanced contractile function.  These results represent the first of its kind in 
single hiPSC-CMs and demonstrate the utility of implementation of the Matrigel mattress and 
hysteresis loops analysis to provide an enhanced data set for drug screening and mechanistic 
assessment. 
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Figure 48.  hiPSC-CM hysteresis loops. A, Extracellular Ca hysteresis loop, normalized peak 
cell shortening amplitude is plotted as a function of normalized peak Ca transient amplitude. 
Data show upward shift of the loop (Positive inotrope). Data are transformed from (Figure 44). 
B, EMD57033 hysteresis loop, normalized peak cell shortening amplitude is plotted as a 
function of normalized peak Ca transient amplitude. Data show upward left shift of the loop (Ca 
sensitizer). Data are transformed from (Figure 43). C Verapamil hysteresis loop, normalized 
peak cell shortening amplitude is plotted as a function of normalized peak Ca transient 
amplitude.  Data show downward shift of the loop (Negative inotrope).  Data are transformed 
from (Figure 45). Isoproterenol hysteresis loop, normalized peak cell shortening amplitude is 
plotted as a function of normalized peak Ca transient amplitude.  Data show upward shift of the 
loop (Positive inotrope).  Data are transformed from (Figure 46).  Veh (Vehicle).  A-D, Y-axis is 
set to different scale to illustrate the differences in hysteresis loop morphology. 
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Discovery of a novel inotrope for heart failure 
EHF1 increases contractility and rates in hiPSC-CMs 
EHF1 was originally identified as a potential hit in a zebrafish HTS screening assay.  
With the establishment of the Matrigel mattress method we assessed EHF1 inotropic potential in 
hiPSC-CMs.  Treatment of hiPSC-CMs with EHF1 (10 µM) resulted in significantly increased 
contractility (i.e., cell shortening) (Figure 49 A and B) compared to vehicle treatments.  In 
addition EHF1 results in significantly faster contraction rate and markedly increased relaxation 
rate (Figure 49 B).  Therefore with the implementation of the mattress platform we identify a 
novel inotrope with efficacy in human CMs. 
EHF1 has negligible effect on Ca handling in hiPSC-CMs 
To determine a potential mechanism for the EHF1 inotropic effect I evaluated the effect 
of EHF1 on hiPSC-CM Ca handling properties.  hiPSC-CMs were loaded with Fura-2 and 
exposed to EHF1 (10 µM) and Ca handling assessed.  In contrast to the contractile response, I 
found EHF1 has negligible effect on hiPSC-CM Ca handling and kinetics (Figure 50) resulting in 
no significant change on Ca handling parameters.  To investigate the chronotropic effect of 
EHF1 I treated hiPSC-CMs with EHF1 10 µM and evaluated beat rate.  I found that EHF1 had 
no effect on hiPSC-CM heart rate (Figure 51) relative to vehicle treated control, in contrast to 
the traditional chronotrope Isoproterenol that significantly increased beat rate in hiPSC-CMs 
(Figure 51). 
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Figure 49. EHF1 contractile response.  A, Representative contraction trace for hiPSC-CM 
treated with vehicle (black) and EHF1 (red) [10µM].  B, Data are mean ± SEM. n = 16. *P<0.05 
vs vehicle (VEH).  Data show EHF1 significantly increases maximum contraction and 
contraction rate in hiPSC-CMs. 
  
130 
Figure 50.  EHF1 Ca handling properties.  A, Representative Ca twitch transients for hiPSC-CM 
treated with vehicle (black) and EHF1 (red) [10µM].  B, Summary data mean ± SEM. n=9 -10 
per group. *P<0.05 vs vehicle (VEH).  Data show EHF1 has negligible effect on hiPSC-CMs 
twitch Ca transient parameters. 
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Figure 51.  Chronotropic response.  Beat rate analysis for hiPSC-CMs treated with EHF1 [10 
µM], β-adrenergic agonist Isoproterenol (ISO) [10 µM], and vehicle (Veh).  N=6 – 8 per group.  
*P<0.05 vs vehicle (VEH).  Graph shows EHF1 has negligible effect on beat rate in hiPSC-CMs. 
And the positive chronotrope, Isoproterenol, significantly increases beat rate in hiPSC-CMs. 
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4.5 Discussion 
Despite recent medical advances, the HF prognosis remains poor with over 50% 
mortality within 5 years of diagnosis. Currently, apart from orthotopic heart transplantation 
(OHT) and mechanical left ventricular assist device (LVAD), treatment options are largely 
palliative.  Moreover, neither OHT nor LVAD comes remotely close to meeting this unmet 
medical need, and both are associated with significant morbidity and mortality.  To exacerbate 
the situation, there have been few drugs approved for treatment of systolic heart failure in the 
past decades, and with recent costly and spectacular failures.  This is thought to be in part 
because of the lack of human CM for drug screening and toxicology assessment. 
Here, I demonstrate hiPSC-CMs may meet this unmet need.  I demonstrate hiPSC-CMs 
represent a valuable in vitro human CM source for drug screening and cardiotoxicity.  Major 
findings are: 1) implementation of the Matrigel mattress enables simultaneous assessment of 
contractile and Ca response to pharmacological agents in single hiPSC-CM (Figure 44 A).  2) 
hiPSC-CMs respond appropriately to pharmacological stimuli and are amenable to 
concentration response curves and EC50 (Figure 45 B and C).  3) I demonstrate for the first time 
single hiPSC-CMs respond appropriately to myofilament Ca sensitizers; this finding would be 
difficult to observe on standard culture substrates (Figure 43).  4) Addition of hysteresis loop 
analysis enables detailed assessment of potential mechanisms in hiPSC-CMs (Figure 48).  5)  
We identify EHF1 as a novel inotrope using hiPC-CMs as a model (Figure 49).  
In critically ill patients with end-stage heart failure, positive inotropes like milrinone and 
dobutamine are invaluable to augment function of failing heart in the intensive care unit setting. 
However, long-term administration of inotropes is limited by drug tolerance, and increased risk 
of arrhythmia, heart failure progression and death.  The underlying mechanism is thought to be 
negative feedback regulation of chronic adrenergic stimulation, chronic cAMP elevation and 
alterations in Ca handling.  Given these issues, there is presently an unmet need for novel 
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drugs that enhance heart function without the adverse effects of the currently available 
medications.  These data suggest EHF1 class of compounds may be useful in this effort.  
Importantly, unlike adrenergic agonists, EHF1 increases contraction (Figure 49) without 
increasing heart rate (Figure 51).  Moreover, EHF1 does not lead to alterations in intracellular 
Ca handling in hiPSC-CMs (Figure 50) which may alleviate abnormal pathological Ca handling 
properties. 
Limitations 
These experiments were performed in spontaneously beating hiPSC-CMs and may 
overlook consequences of different cycle lengths on hiPSC-CM function.  Likewise, all 
experiments were performed at room temperature; it will be interesting to see if physiologic 
temperatures enhance key findings.  The lack of robust inotropic contractile and Ca amplitude 
response to β-adrenergic receptor agonists is in contrast to expected results in adult-CMs.  This 
suggests that while I provide evidence for maturation of key aspects of hiPSC-CMs work still 
needs to be done to achieve the adult phenotype. 
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Chapter 5 
CONCLUSIONS 
Although promising, the full potential of hiPSC-CMs has yet to be revealed.  After the 
initial excitement surrounding the discovery of hiPSC-CM, researchers had begun transplanting 
hPSC-CM into animal models (e.g., non-human primates) post infarct, before an in-depth 
understanding of hiPSC-CM EC coupling properties have been established.  While preliminary 
results from these studies appear promising as assessed by successful engraftment, re-
muscularization and perfusion by host vasculature [53], there remains the looming issue of the 
increased arrhythmic events in these studies.  For this reason the main focus in the stem cell 
field has been to develop strategies to generate more mature hiPSC-CMs. To model human 
heart in vitro and to also withstand proper engraftment and physiological performance for cell 
therapies and heart regeneration.  As a first step in this effort I set out to define the EC coupling 
properties of normal hiPSC-CMs, providing a foundation for future applications including 
transplantation. 
Here, I characterize the EC coupling properties of normal hiPSC-CMs (Chapter 2) 
specifically focusing on electrophysiological properties and Ca handling properties and develop 
a novel culture method to assess hiPSC-CM contractile properties.  Our studies of normal 
hiPSC-CM demonstrate hiPSC-CMs exhibit relatively mature EC coupling properties which are 
comparable between hiPSC-CMs generated at different institutions and that of adult-CMs 
studied under identical experimental conditions.  Of note, our results that hiPSC-CM EC 
coupling properties are consistent across hiPSC-CMs recovered from cryopreservation enables 
standardization of hiPSC-CM use for basic science and drug discovery, as well as large scale 
studies (i.e., > one billion hiPSC-CMs) necessary for human transplantation.  To the best of our 
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knowledge this represents the first systematic characterization of hiPSC-CM EC coupling 
properties. 
While I demonstrate many aspects of hiPSC-CM EC coupling are comparable to adult 
CMs it is important to note that these are not adult CM, this is demonstrated structurally by our 
morphological studies showing hiPSC-CMs are underdeveloped (i.e., smaller) relative to adult 
CMs and functionally in electrophysiological analysis by their reduced upstroke velocity and lack 
of the notch in the action potential morphology and in Ca handling studies by decreased Ca 
decay rate.  Future studies will incorporate and assess EC coupling in single hiPSC-CMs 
generated using a combination of approaches that further increase hiPSC-CM maturity (e.g., 2D 
patterning [54], electrical stimulation [55] and 3D culture methods [56]).  For example, Rao et al. 
reported a faster time to peak and improved SR function of hiPSC-CMs cultured on 
micropatterned substrates compared to unstructured polydimethylsiloxane membranes [54]. 
I further demonstrate utility of hiPSC-CMs for disease modeling (Chapter 3) and 
recapitulate previous sarcomeric cardiomyopathy findings in hiPSC-CMs, supporting the 
reproducibility of this model for disease modeling.  In addition I provide mechanistic insight for 
altered function of HCM hiPSC-CMs.  For example, I provide evidence that HCM hiPSC-CMs 
display altered twitch Ca removal and increased Ca sensitivity supporting an increased Ca 
affinity hypothesis.  Moreover, with the implementation of the mattress culture method I elucidate 
previously undiscovered contractile defects, myofilament sensitivity defects and arrhythmic 
abnormalities of diseased hiPSC-CMs, at the single cell level.  While promising, these studies do 
not assess the hiPSC-CM cytosolic Ca buffering properties.  For instance, it is well accepted 
that cytoplasmic binding sites such as troponin C play a significant role in buffering cytosolic Ca.  
And changes in Ca buffering, or Ca affinity, may lead to alterations of twitch Ca handling 
properties and ultimately contractile properties resulting in pathological consequence.  Future 
studies will assess the physiological consequences of the RCM troponin I mutation on altered Ca 
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sensitivity by implementation of the Matrigel mattress and hysteresis loop analysis, as above.  
Toward that end we are currently evaluating the Ca buffering properties of diseased hiPSC-CMs 
presented here. 
With the addition of pharmacological analysis (Chapter 4) I show normal hiPSC-CMs 
demonstrate appropriate responses to known pharmacological compounds that modulate EC 
coupling, for example modulation of extracellular Ca (e.g., verapamil) as well as myofilament Ca 
sensitizers such as EMD57033.  Future studies using our novel contractility platform will be 
focused on defining hiPSC-CM pharmacological responses to large panel of known agents, 
including EC50 values and compare these results to those obtained for adult animal CMs (e.g., 
rabbit-CM) studied under identical experimental conditions.  Moreover, in their current form, I 
demonstrate utility of hiPSC-CMs for identifying novel inotropic compounds such as EHF1.  
Future studies will determine the relevant physiological target of EHF1 inotropic effect in hiPSC-
CM.  In addition to miniaturization of the Matrigel mattress for high throughput screening of 
novel cardioactive compounds. 
137 
APPENDIX 
 
Table A-1.  qRT-PCR primers and descriptions.  qRT-PCR primers used for Matrigel mattress 
molecular profiling (Figure 27 and Figure A-1). 
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Figure A-1.  Matrigel mattress qRT-PCR screen.  Data are presented as fold change as above 
(Figure 27).  Day 30-35 mattress and control hiPSC-CM transcripts were normalized to 
housekeeping gene 18S rRNA.  Data show differential molecular profile of Matrigel mattress 
hiPSC-CMs after 5 days of culture on the Matrigel mattress..  Courtesy of Mr. Adrian C Gadar. 
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